<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004284.pub2" GROUP_ID="LUNGCA" ID="829503011509383348" MERGED_FROM="" MODIFIED="2012-10-29 11:22:33 +0000" MODIFIED_BY="Sera Tort" REVIEW_NO="ACZ1" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2012-10-26 14:21:07 +0200" MODIFIED_BY="Ludovic Reveiz">
<TITLE>Palliative endobronchial brachytherapy for non-small cell lung cancer</TITLE>
<CONTACT>
<PERSON ID="14522" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Ludovic</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Reveiz</LAST_NAME>
<SUFFIX>MD, MSc, PhD (Cand)</SUFFIX>
<POSITION>Advisor</POSITION>
<EMAIL_1>mmreveiz@hotmail.com</EMAIL_1>
<EMAIL_2>lreveiz@yahoo.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Research Promotion and Development Team</DEPARTMENT>
<ORGANISATION>Health Systems Based on Primary Health Care (HSS), Pan American Health Organization</ORGANISATION>
<ADDRESS_1>525, 23rd St, NW</ADDRESS_1>
<ADDRESS_2/>
<CITY>Washington DC</CITY>
<ZIP>20037-2895</ZIP>
<REGION/>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1/>
<PHONE_2>+1 202 974 3135</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-10-26 14:21:07 +0200" MODIFIED_BY="Ludovic Reveiz">
<PERSON ID="14522" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Ludovic</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Reveiz</LAST_NAME>
<SUFFIX>MD, MSc, PhD (Cand)</SUFFIX>
<POSITION>Advisor</POSITION>
<EMAIL_1>mmreveiz@hotmail.com</EMAIL_1>
<EMAIL_2>lreveiz@yahoo.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Research Promotion and Development Team</DEPARTMENT>
<ORGANISATION>Health Systems Based on Primary Health Care (HSS), Pan American Health Organization</ORGANISATION>
<ADDRESS_1>525, 23rd St, NW</ADDRESS_1>
<ADDRESS_2/>
<CITY>Washington DC</CITY>
<ZIP>20037-2895</ZIP>
<REGION/>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1/>
<PHONE_2>+1 202 974 3135</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="1BC78FA582E26AA200CF0384DB5FCFBE" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>José-Ramón</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rueda</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Teacher</POSITION>
<EMAIL_1>joseramon.rueda@ehu.es</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+34-656734086</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Preventive Medicine and Public Health. GIU 10/24.</DEPARTMENT>
<ORGANISATION>University of the Basque Country</ORGANISATION>
<ADDRESS_1>Barrio Sarriena</ADDRESS_1>
<ADDRESS_2>S.N.</ADDRESS_2>
<CITY>Leioa</CITY>
<ZIP>E-48080</ZIP>
<REGION>Bizkaia</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 94 601 3421</PHONE_1>
<PHONE_2/>
<FAX_1>+34 94 601 3393</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14497" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Andrés Felipe</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cardona</LAST_NAME>
<SUFFIX>MD, MSc, PhDc</SUFFIX>
<POSITION>Clinical Oncologist</POSITION>
<EMAIL_1>a_cardonaz@yahoo.com</EMAIL_1>
<EMAIL_2>acardonaz@yahoo.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical and Translational Oncology Group</DEPARTMENT>
<ORGANISATION>Institute of Oncology, Fundación Santa Fe de Bogotá</ORGANISATION>
<ADDRESS_1>Calle 119 No. 7 - 75</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bogotá</CITY>
<ZIP>0571</ZIP>
<REGION>Cundinamarca</REGION>
<COUNTRY CODE="CO">Colombia</COUNTRY>
<PHONE_1>+571 6030303 (5227)</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2002-03-13 05:54:42 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="2" MONTH="10" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="1" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="3" MONTH="10" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2002-03-13 05:54:19 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2002-03-13 05:54:11 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="10" YEAR="2012"/>
<DESCRIPTION>
<P>First author changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2002-03-13 05:54:19 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="10" YEAR="2012"/>
<DESCRIPTION>
<P>We included one new RCT in the review. We assessed the studies for risk of bias.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="20" MONTH="12" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-07-18 14:51:26 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2012-07-18 14:51:15 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-07-18 14:51:15 +0200" MODIFIED_BY="[Empty name]">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2012-07-18 14:51:26 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-07-18 14:51:26 +0200" MODIFIED_BY="[Empty name]">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-10-29 12:09:26 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-10-29 12:08:11 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Endobronchial brachytherapy as palliative care for people with inoperable non-small cell lung cancer</TITLE>
<SUMMARY_BODY MODIFIED="2012-10-29 12:08:11 +0100" MODIFIED_BY="[Empty name]">
<P>This is an updated version of the original review published in Issue 2, 2008 of <I>The Cochrane Library</I>. Patients with inoperable non-small cell lung cancer (NSCLC) have a poor prognosis and the treatment options are limited to controlling their symptoms and maintaining their quality of life. Palliative endobronchial brachytherapy (EBB) is sometimes used to improve local control of the tumor, and the patient's symptoms and quality of life. Endobronchial brachytherapy is a procedure that involves placing radioactive material inside the patient's airways as an 'internal radiotherapy'.</P>
<P>We were not able to provide conclusive evidence from randomized controlled trials to support the use of EBB in combination with external beam radiation therapy (EBRT), chemotherapy or neodymium:yttrium-aluminum-garnet (Nd-YAG) laser.</P>
<P>From heterogeneous information obtained from several small RCTs, we conclude that EBRT alone is more effective for palliation than EBB alone. If patients who previously were treated with EBRT develop symptoms from the tumour growing again in the main airways, EBB may in some cases be an appropriate treatment to consider.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-10-29 12:07:21 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2002-03-13 04:08:25 +0100" MODIFIED_BY="[Empty name]">
<P>This is an updated version of the original review published in Issue 2, 2008 of <I>The Cochrane Library</I>. Non-small cell lung cancers (NSCLC) constitute about 80% of all lung cancer cases. Although surgery is the only curative treatment of NSCLC, fewer than 20% of tumors can be radically resected. Radiotherapy is one of the main treatment modalities in lung cancer, contributing to both its cure and palliation. Endobronchial brachytherapy (EBB) has been used as one approach to improve local control either alone or in combination with other treatments.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-10-26 14:25:08 +0200" MODIFIED_BY="[Empty name]">
<P>To assess the effectiveness of palliative EBB compared with external beam radiation therapy (EBRT) or other alternative endoluminal treatments in controlling thoracic symptoms and increasing survival in patients with advanced NSCLC.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-10-29 06:45:13 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL,<I>The Cochrane Library, </I>Issue 1 2012), MEDLINE (OvidSP) (1966 to January 2012), EMBASE (Ovid) (1974 to January 2012) and other databases as well as reference lists, and we handsearched selected journals and conference proceedings.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized controlled trials (RCTs) comparing different regimens of palliative EBB with EBRT or other endobronchial interventions in patients with advanced NSCLC.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2002-03-13 04:09:54 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently extracted data and conducted risk of bias assessment.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-10-29 06:46:57 +0100" MODIFIED_BY="[Empty name]">
<P>We included fourteen RCTs involving 953 participants. We included a new study assessing a variety of different fractionation schedules of high dose rate palliative EBB in this update. There were important differences in the doses of radiotherapy investigated, in the patient characteristics and in the outcomes measured. We found trials comparing EBB to EBRT alone, EBB plus EBRT to EBRT alone, EBB plus chemotherapy to EBB alone, EBB to neodymium: yttrium-aluminum-garnet (Nd-YAG) laser and comparisons between various fractionation schedules of high dose rate EBB. From the heterogeneous information obtained from several small RCTs, we concluded that EBRT alone is more effective for palliation of NSCLC symptoms than EBB alone. Our findings did not provide conclusive evidence to recommend EBB plus EBRT to relieve symptoms compared to EBRT alone. Overall, for the primary endpoint of survival there was no evidence of benefit for EBB compared to EBRT and Nd-YAG laser or for the combination of EBB with chemotherapy. Additionally, findings from one trial suggested that twice 7.4 Gy was superior to the four times per week 3.8 Gy schedule for mean time of local control and fatal hemoptysis. No significant differences were found for fatal hemoptysis as an adverse event of EBB.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-10-29 12:07:21 +0100" MODIFIED_BY="[Empty name]">
<P>The evidence did not provide conclusive results that EBB plus EBRT improved symptom relief over EBRT alone. We were not able to provide conclusive evidence to recommend EBB with EBRT, EBB in preference to EBRT, chemotherapy or Nd-YAG laser. From heterogeneous information obtained from several small RCTs, we conclude that EBRT alone is more effective for palliation than EBB alone. For patients previously treated by EBRT who are symptomatic from recurrent endobronchial central obstruction, EBB may be considered in selected cases.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-10-29 12:09:26 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-10-29 12:09:04 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2012-10-29 12:09:04 +0100" MODIFIED_BY="[Empty name]">
<P>This is an updated version of the original review published in Issue 2, 2008 of <I>The Cochrane Library </I>(<LINK REF="REF-Cardona-2008" TYPE="REFERENCE">Cardona 2008</LINK>).</P>
<P>The very high incidence of lung cancer in the modern industrial world and its high mortality rate offers considerable challenges to the oncology community. Although the incidence of lung cancer in men in the developed world is currently decreasing, it is rising in some developing countries and it is the main cause of death from all cancers worldwide (<LINK REF="REF-Becket-1993" TYPE="REFERENCE">Becket 1993</LINK>; <LINK REF="REF-Boyle-2000" TYPE="REFERENCE">Boyle 2000</LINK>; <LINK REF="REF-Globocan-IARC-2002" TYPE="REFERENCE">Globocan IARC 2002</LINK>; <LINK REF="REF-ACS-2010" TYPE="REFERENCE">ACS 2010</LINK>).</P>
<P>Between 75% and 85% of lung cancer patients have non-small cell lung cancer (NSCLC), of whom approximately 20% to 30% will have tumors that are potentially curable with surgical resection (<LINK REF="REF-Paradelo-1992" TYPE="REFERENCE">Paradelo 1992</LINK>; <LINK REF="STD-Huber-1995" TYPE="STUDY">Huber 1995</LINK>). Treatments for advanced NSCLC often include some form of radiation therapy (<LINK REF="REF-Maher-1993" TYPE="REFERENCE">Maher 1993</LINK>; <LINK REF="REF-Emami-1997" TYPE="REFERENCE">Emami 1997</LINK>). Vinod et al reported an underuse of radiotherapy for lung cancer, especially in small cell lung cancer (<LINK REF="REF-Vinod-2010" TYPE="REFERENCE">Vinod 2010</LINK>). Regimens for palliative radiotherapy had not been evaluated rigorously in clinical trials until the late 1980s and 1990s (<LINK REF="REF-Lester-2006" TYPE="REFERENCE">Lester 2006</LINK>) when research evolved from clinical experience to thorough assessment in clinical trials investigating different palliative schedules. Rates of symptom relief were shown to be between 48% and 80% in inoperable NSCLC (<LINK REF="REF-Maher-1993" TYPE="REFERENCE">Maher 1993</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]">
<P>In a previous Cochrane review designed to evaluate the most effective and least toxic regimen for palliative EBRT in patients with advanced NSCLC, the authors concluded that this treatment appeared to be effective in controlling troublesome symptoms from intrathoracic tumor. They recommended that the majority of individuals should be treated with short courses of EBRT (such as 10 Gy in 1 fraction or 16 to 17 Gy in 2 fractions) and in cases with good performance status, to use higher dose regimens (such as 36 Gy in 12 fractions); nevertheless, they found that more research was needed to assess definitive effectiveness and tolerability of palliative EBRT (<LINK REF="REF-Lester-2006" TYPE="REFERENCE">Lester 2006</LINK>). Local treatment of bronchial occlusion may be beneficial since obstruction is an important determinant of the quality of life. In the management of endobronchial disease, brachytherapy, laser resection, cryosurgery, electrocautery, endobronchial surgery or endoluminal prosthesis (stent) placement may help to reduce airway obstruction (<LINK REF="REF-Paradelo-1992" TYPE="REFERENCE">Paradelo 1992</LINK>; <LINK REF="REF-Shaw-1993" TYPE="REFERENCE">Shaw 1993</LINK>).</P>
<P>Endobronchial brachytherapy (EBB) has been used as one approach to improve local control, either alone or in combination with other treatments (<LINK REF="REF-Paradelo-1992" TYPE="REFERENCE">Paradelo 1992</LINK>). The theoretical advantages of EBB are delivery of a higher radiation dose to the tumor, a rapid decrease of dose outside the treated volume, precise dose localization and adaptability to tumor shape. The use of brachytherapy has increased in recent years due to several innovative technologic advances that include low-energy iodine-125 and palladium-103 radionuclides, high dose rate (HDR) remote afterloading, computerized dosimetry and the use of newer imaging techniques (<LINK REF="REF-Schray-1988" TYPE="REFERENCE">Schray 1988</LINK>; <LINK REF="REF-Hilaris-1994" TYPE="REFERENCE">Hilaris 1994</LINK>; <LINK REF="REF-Wang-2011" TYPE="REFERENCE">Wang 2011</LINK>; <LINK REF="REF-Sutherland-2012" TYPE="REFERENCE">Sutherland 2012</LINK>). Other endoscopic treatments such as stenting, which are much easier to organize, are also frequently used to provide rapid relief of symptoms (<LINK REF="REF-Gompelmann-2011" TYPE="REFERENCE">Gompelmann 2011</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2012-10-26 14:43:08 +0200" MODIFIED_BY="[Empty name]">
<P>Brachytherapy for lung carcinoma can be categorized into interstitial and intraluminal techniques. Intraluminal (endobronchial) techniques were introduced in the early 1920s. Most commonly, interstitial implantation is used at the time of surgical resection and is placed percutaneously or by thoracoscopy. EBB is divided into low, intermediate and high dose rate (HDR) applications and refers to the temporary placement of the isotope into the tracheobronchial tree (<LINK REF="REF-Burt-1987" TYPE="REFERENCE">Burt 1987</LINK> <LINK REF="REF-Schray-1988" TYPE="REFERENCE">Schray 1988</LINK>; <LINK REF="REF-Speiser-1999" TYPE="REFERENCE">Speiser 1999</LINK>). Low-dose EBB consists of insertion of an isotope strand delivering doses less than 1 Gy/hr (total dose about 30 Gy) in the bronchus; high-dose EBB provides doses of more than 10 Gy/hr (total dose, 20 to 40 Gy) (<LINK REF="REF-Schray-1988" TYPE="REFERENCE">Schray 1988</LINK>). Two to four treatments are usually delivered about one week apart.</P>
</THEORY>
<IMPORTANCE MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]">
<P>In earlier studies, EBB was particularly used as palliative treatment for endobronchial recurrences after EBRT. Later EBB was combined with EBRT and other interventions to control respiratory symptoms, achieving 90% improvement in hemoptysis, 85% for cough, 86% for dyspnea and 99% for postobstructive pneumonia and atelectasis (<LINK REF="REF-Seagren-1985" TYPE="REFERENCE">Seagren 1985</LINK>; <LINK REF="REF-Chang-1994" TYPE="REFERENCE">Chang 1994</LINK>). More recently, a systematic overview of radiation therapy effects in NSCLC revealed that EBB appeared to be less effective than EBRT (<LINK REF="REF-Sirz_x00e9_n-2003" TYPE="REFERENCE">Sirzén 2003</LINK>). The most serious complications described with EBB were massive hemoptysis, formation of tracheoesophageal fistulas, bronchospasm, bronchial stenosis and radiation bronchitis (<LINK REF="REF-Perez-1992" TYPE="REFERENCE">Perez 1992</LINK>). There is no evidence to routinely recommend EBB alone or in conjunction with other palliative maneuvers in the initial palliative management of endobronchial obstruction resulting from lung cancer. According to a recent consensus statement on palliative lung radiotherapy, there is currently no evidence to routinely recommend EBB with palliative intent and prospective randomized trials are needed to better define its role (<LINK REF="REF-Rodrigues-2012" TYPE="REFERENCE">Rodrigues 2012</LINK>).</P>
<P>The aim of this review update was to determine if EBB is more effective and better tolerated than EBRT or other endobronchial interventions in patients with symptomatic endobronchial disease due to advanced NSCLC. Additionally, we set out to evaluate the most effective and least toxic dose of EBB.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-10-09 11:06:55 +0200" MODIFIED_BY="[Empty name]">
<P>The primary objective of this review was to assess the effectiveness of palliative EBB in controlling thoracic symptoms in patients with advanced NSCLC. A secondary objective was to assess the effectiveness in increasing survival and adverse events. EBB was compared with EBRT or other endoluminal treatments (laser, cryosurgery, electrocautery, endosurgery and stent applications). Additionally, we evaluated the optimal dose regimen of palliative EBB, the best fractionation schedule and the associated rates of adverse events; and the association of EBB and EBRT.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-10-29 06:50:21 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]">
<P>Studies were included if they were a journal publication of a randomized controlled trial (RCT) of palliative EBB for advanced NSCLC. Abstracts and proceedings of relevant scientific meetings or information achieved by direct contact with investigators were also considered for inclusion. We excluded reports of EBB for non-palliative management of NSCLC, concurrent cohort comparisons and other non-experimental designs.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with confirmed lung cancer of non-small cell type that was metastatic or locally advanced (stage IIIb and IV) with endoluminal tumor of the trachea, main stem or lobar bronchi and with recurrent or persistent thoracic symptoms (hemoptysis, cough, dyspnea, and postobstructive pneumonitis).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]">
<P>Endobronchial brachytherapy (high and low dose rates) with palliative intent (that is with the aim of controlling symptoms and not cure) with different techniques, doses and fractions compared with either EBRT, other endoluminal procedures, chemotherapy or best supportive care for patients with advanced NSCLC. Combination treatments with external radiotherapy, laser photoresection and endobronchial surgery with or without diathermy were considered for inclusion.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]">
<P>We considered the following outcome measures in this review:</P>
<UL>
<LI>improvement in major thoracic symptoms (degree and duration) as assessed by patient and doctor;</LI>
<LI>quality of life (QOL) or functional status measured by standard and valid instruments (i.e. assessed using the Eastern Cooperative Oncology Group (ECOG) score or Karnofsky index);</LI>
<LI>radiological improvement;</LI>
<LI>short- and long-term toxicity;</LI>
<LI>survival from date of randomization;</LI>
<LI>cause of death;</LI>
<LI>degree of endobronchial obstruction, if available; and</LI>
<LI>patient convenience and acceptability.</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2002-03-13 05:07:04 +0100" MODIFIED_BY="[Empty name]">
<P>This is an updated version of the original review published in Issue 2, 2008 of <I>The Cochrane Library</I>; we updated the searches. We systematically searched the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I> 2012, Issue 1), MEDLINE (1966 to January 2012) and EMBASE (1974 to January 2012) using the OvidSP software system. We applied the search strategies of the Cochrane Lung Cancer Review Group (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) as appropriate to each of the databases and, furthermore, added specific search terms to the strategy for each respective database (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)</P>
<P>Additional strategies for LILACS (1982 to January 2012) (<LINK REF="REF-Castro-1999" TYPE="REFERENCE">Castro 1999</LINK>) were designed using similar criteria (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). We also searched references of review articles and chapters of books related to lung cancer brachytherapy. We contacted leading researchers involved in the field by email to obtain additional published and unpublished data. In addition, we searched the International Clinical Trials Registry Platform to identify ongoing trials (key terms: "brachytherapy"; "Lung" OR "non small cell").</P>
<P>There were no language or date restrictions in the searches.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-10-29 06:50:21 +0100" MODIFIED_BY="[Empty name]">
<P>We intended to summarize data by standard Cochrane Collaboration methodologies (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).<BR/>
</P>
<STUDY_SELECTION MODIFIED="2002-03-13 04:16:52 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (AFC and LR) checked the titles and abstracts identified from the searches. If it was clear that the study did not refer to a randomized controlled trial on EBB with palliative intent for advanced NSCLC, it was excluded. If it was unclear, then the full-text study was obtained for independent assessment by two review authors (JRR and LR). The review authors decided which trials met the inclusion criteria. Any disagreements were resolved by discussion, with referral to a third review author when necessary. Excluded studies and reasons for exclusion are described in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2002-03-13 04:17:11 +0100" MODIFIED_BY="[Empty name]">
<P>One review author (LR) independently extracted data using a pre-designed data extraction form to collect publication details, patient population, randomization, allocation concealment, details of blinding measures, description of interventions and results. Data extraction was checked by another author (AFC). Disagreements were resolved by consensus. Missing data were obtained from study authors, where possible.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (LR, JRR) independently assessed the risk of bias of each trial using a simple form, and followed the domain-based evaluation as described in the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Review authors discussed any discrepancies and achieved consensus on the final assessment.</P>
<P>We assessed the following domains as low risk of bias, unclear or high risk of bias:</P>
<OL>
<LI>Generation of allocation sequence</LI>
<LI>Allocation concealment</LI>
<LI>Blinding (of participants, personnel and outcome assessors)</LI>
<LI>Incomplete outcome data</LI>
<LI>Selective reporting</LI>
<LI>Other sources of bias</LI>
</OL>
<SUBSECTION>
<HEADING LEVEL="4">(1) Generation of allocation sequence (checking for possible selection bias)</HEADING>
<P>For each included study we described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI>Low risk (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>High risk (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);</LI>
<LI>Unclear risk, if the trial was described as randomized, but the method used for the allocation sequence generation was not described.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>For each included study we described the method used to conceal the allocation sequence in sufficient detail and determine whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>Low risk (e.g. telephone or central randomization; consecutively numbered sealed opaque envelopes);</LI>
<LI>High risk (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>Unclear risk, if the trial was described as randomized, but the method used to conceal the allocation was not described.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Blinding or masking (checking for possible performance bias)</HEADING>
<P>For each included study we described the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We judged studies at low risk of bias if they were blinded, or if we judged that the lack of blinding could not have affected the results. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>Low risk, high risk or unclear for participants;</LI>
<LI>Low risk, high risk or unclear for personnel;</LI>
<LI>Low risk, high risk or unclear for outcome assessors.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations)</HEADING>
<P>We assessed the methods as:</P>
<UL>
<LI>Low risk (any one of the following): No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically-relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically-relevant impact on observed effect size; missing data have been imputed using appropriate methods.</LI>
</UL>
<UL>
<LI>High risk (any one of the following): reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically-relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically-relevant bias in observed effect size; &#8216;As-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomization; potentially inappropriate application of simple imputation.</LI>
</UL>
<UL>
<LI>Unclear risk (any one of the following): insufficient reporting of attrition/exclusions to permit judgement of &#8216;Low risk&#8217; or &#8216;High risk&#8217; (e.g. number randomized not stated, no reasons for missing data provided); the study did not address this outcome.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting bias (reporting bias due to selective outcome reporting)</HEADING>
<P>For each included study we described how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>Low risk (any one of the following): the study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way or the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</LI>
</UL>
<UL>
<LI>High risk (any one of the following): not all of the study&#8217;s pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. sub scales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.</LI>
</UL>
<UL>
<LI>Unclear risk: insufficient information to permit judgement of &#8216;Low risk&#8217; or &#8216;High risk&#8217;.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Free of other bias (bias due to problems not covered elsewhere in the table)</HEADING>
<P>For each included study we described any important concerns we have about other possible sources of bias (e.g. baseline imbalance, sponsorship bias, confirmation bias, bias of the presentation data, etc.)</P>
<UL>
<LI>Low risk of bias, the trial appears to be free of other components that could put it at risk of bias;</LI>
<LI>Unclear risk, the trial may or may not be free of other components that could put it at risk of bias;</LI>
<LI>High risk of bias, there are other factors in the trial that could put it at risk of bias, e.g., no sample size calculation made, academic fraud, industry involvement, or extreme baseline imbalance.</LI>
</UL>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-06-27 18:20:41 +0200" MODIFIED_BY="[Empty name]">
<P>We quantified statistical heterogeneity using the I<SUP>2 </SUP>statistic, which describes the percentage of total variation across trials due to heterogeneity rather than sampling error. We considered significant statistical heterogeneity to be present if I<SUP>2 </SUP>was greater than<SUP> </SUP>50% (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]">
<P>We did not attempt to assess whether the review is subject to publication bias by using a funnel plot to illustrate variability graphically between trials. None of the comparison that were assessed had 10 or more RCTs.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]">
<P>We expressed the results as relative risk (RR) and 95% confidence intervals (CIs) for dichotomous outcomes and mean difference (MD) and 95% CIs for continuous outcomes. We carried out statistical analysis using the Review Manager software. We used fixed-effect meta-analysis for combining data in the absence of significant heterogeneity. If significant heterogeneity was found, we used the random-effects model.We summarized the information available. Quasi-randomized and non-randomized controlled studies were identified and listed but were not further discussed. For the pooled analysis, we calculated the I<SUP>2</SUP> statistic, which describes the percentage of total variation across studies caused by heterogeneity; less than 25% was considered as low level heterogeneity; 25% to 50% as moderate level, and higher than 50% as high level heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>For most comparisons it was not possible to carry out a quantitative analysis because of the multiple sources of heterogeneity between included studies (different interventions in control groups, quality of studies, full data publication, tumor stage, brachytherapy total dose and fractionation schedule, degree of bronchial obstruction, methods of symptom and quality of life assessment). We therefore performed a qualitative review and synthesis of the selected reports.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-10-29 06:50:21 +0100" MODIFIED_BY="[Empty name]">
<P>Even though we had planned to perform separate analysis for some subgroups of patients, this proved not to be possible because of the lack of necessary data. If information is available, future updates of this review will present separate analysis for:</P>
<OL>
<LI>Risk of bias assessment (low, intermediate, high)</LI>
<LI>Tumor stage</LI>
<LI>Doses, schedule</LI>
<LI>Degree of bronchial obstruction</LI>
</OL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2002-03-13 04:21:04 +0100" MODIFIED_BY="[Empty name]">
<P>For future updates, we plan to perform sensitivity analysis by systematically excluding studies from the overall analysis based on the potential sources of heterogeneity hypothesized above, and if homogeneous subgroups have not already been identified and analysed separately (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-10-26 14:47:28 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-10-26 14:46:41 +0200" MODIFIED_BY="[Empty name]">
<P>From the results of the extensive literature search, we initially identified 813 citations as potentially relevant. Thirty-six references were considered as possible RCTs of EBB alone or in association with other interventions for the palliation of symptoms related to advanced NSCLC. Manual culling reduced this number of references to 14 eligible trials; we excluded 22 reports. Some of the studies included in the review were partial reports presented as conference abstracts. Complementary strategies to identify other relevant studies, unpublished data or ongoing trials were not effective. Compared to the previous version of the review, we located and included one new study (<LINK REF="STD-Mallick-2006" TYPE="STUDY">Mallick 2006</LINK>).</P>
<P>The studies considered in this review compared EBB with EBRT, diverse fractionation schedules of HDR EBB, EBRT versus HDR EEB, EBB versus EBB plus chemotherapy and combined Nd-YAG laser plus EBB versus Nd-YAG laser alone. We found no RCTs that compared palliative EBB with best supportive care, cryosurgery, electrocautery, endosurgery or stent applications. We present detailed descriptions of studies in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. EBRT versus EBRT in combination with EBB</HEADING>
<P>We found six RCTs that compared EBRT with EBRT in combination with EBB (<LINK REF="STD-Baas-1994" TYPE="STUDY">Baas 1994</LINK>; <LINK REF="STD-Huber-1997" TYPE="STUDY">Huber 1997</LINK>; <LINK REF="STD-Sharma-1998" TYPE="STUDY">Sharma 1998</LINK>; <LINK REF="STD-Langendijk-2001" TYPE="STUDY">Langendijk 2001</LINK>; <LINK REF="STD-Sur-2004" TYPE="STUDY">Sur 2004</LINK>; <LINK REF="STD-Mallick-2006" TYPE="STUDY">Mallick 2006</LINK>); three studies were fully published (<LINK REF="STD-Huber-1997" TYPE="STUDY">Huber 1997</LINK>; <LINK REF="STD-Langendijk-2001" TYPE="STUDY">Langendijk 2001</LINK>; <LINK REF="STD-Mallick-2006" TYPE="STUDY">Mallick 2006</LINK>) and the other three RCTs were presented as conference abstracts (<LINK REF="STD-Baas-1994" TYPE="STUDY">Baas 1994</LINK>; <LINK REF="STD-Sharma-1998" TYPE="STUDY">Sharma 1998</LINK>; <LINK REF="STD-Sur-2004" TYPE="STUDY">Sur 2004</LINK>). While we obtained additional information from three authors (<LINK REF="STD-Langendijk-2001" TYPE="STUDY">Langendijk 2001</LINK>; <LINK REF="STD-Mallick-2006" TYPE="STUDY">Mallick 2006</LINK>; <LINK REF="STD-Sharma-1998" TYPE="STUDY">Sharma 1998</LINK>); for some of the older studies we were unable to contact the authors or authors contacted did not provided the requested information. Three additional reports were duplicate publications or published preliminary analysis of included trials (see under <LINK REF="STD-Huber-1997" TYPE="STUDY">Huber 1997</LINK> <LINK REF="STD-Poellinger-2000" TYPE="STUDY">Poellinger 2000</LINK>).</P>
<P>The German trial (<LINK REF="STD-Huber-1997" TYPE="STUDY">Huber 1997</LINK>) considered only candidates for palliative interventions. The Langendijk study (<LINK REF="STD-Langendijk-2001" TYPE="STUDY">Langendijk 2001</LINK>) divided groups according to two fractionation schedules of EBRT: one radical (60 Gy) for patients with stage I or II disease with a tumor diameter &gt; 4 cm or stage IIIa and IIIb disease without supraclavicular lymph node metastases and a WHO (World Health Organization) performance status of 2; the other group included patients with a WHO performance status of 3, with supraclavicular lymph node involvement or distant metastases with symptoms related to intrathoracic tumor, or both. These individuals were considered to have the worst prognosis and were selected for the palliative fractionation schedule using a smaller dose of EBRT (30 Gy). Inclusion of these patients could influence the assessment of effectiveness or toxicity and might affect the survival results. Only 52 patients were stage IIIb and met the inclusion criteria of this systematic review. Both trials used the international staging system for lung cancer as recommended by the American Joint Committee on Cancer (AJCC). In <LINK REF="STD-Langendijk-2001" TYPE="STUDY">Langendijk 2001</LINK>, the follow up began in the fourth week during radiotherapy, when a chest radiograph was made to evaluate whether it was necessary to change the original field set up for the boost because of changes due to re-expansion of atelectasis or postobstructive pneumonia. In case of major changes because of resolution of atelectasis, a new computerized tomography (CT) scan was done for planning and the treatment was adjusted. In <LINK REF="STD-Huber-1997" TYPE="STUDY">Huber 1997</LINK> the first radiographic evaluation was carried out in the third month. Moreover, the scales used to evaluate the quality of life after the treatment were different between studies. Huber 1997 used the Karnofsky index (<LINK REF="STD-Huber-1997" TYPE="STUDY">Huber 1997</LINK>), while <LINK REF="STD-Langendijk-2001" TYPE="STUDY">Langendijk 2001</LINK> used the Dutch version of the EORTC QOL-C30 and the lung cancer module QOL-LC13.</P>
<P>In the concise report of Sharma et al (<LINK REF="STD-Sharma-1998" TYPE="STUDY">Sharma 1998</LINK>) the authors stated that 60 patients with inoperable NSCLC were included and randomized into two groups. All the individuals had endobronchial disease and received a dose of 30 Gy of EBRT divided into 10 fractions over two weeks. The EBB was delivered using a micro-Selectron HDR machine and a dose of 8 Gy at 10 mm from the central axis of the source was administered in two sessions. The clinical profile of both study groups appeared to be comparable.</P>
<P>
<LINK REF="STD-Baas-1994" TYPE="STUDY">Baas 1994</LINK> was presented as an abstract at an international lung cancer meeting. In this short report the authors briefly described the methodology used in the study to evaluate the additional effect of photodynamic therapy and HDR EBB with EBRT in the treatment of patients with advanced NSCLC. The patients had to meet the following conditions to be included: weight loss &lt; 10% and functional status &gt; 70%. The patients were treated using Photofrin (2 mg/kg, 200 J/cm, 630 nm) and EBB (15 Gy at 1 cm distance along the tumor) two weeks before EBRT (14 x 2.5 plus 8 x 2.5 Gy to the tumor area in four weeks). Of the 43 patients included, only 37 presented with stage III disease and the treatment was considered as palliative; of these, 12 patients received EBRT alone, 12 EBRT plus EBB and 15 photodynamic therapy with EBRT.</P>
<P>In another RCT (Sur 2001) 26 patients with advanced, inoperable, biopsy-proven NSCLC received palliative EBRT of 30 Gy in 10 fractions over two weeks. At the end of treatment, patients were randomized to receive further EBRT of 20 Gy in 10 fractions over two weeks (group 1) or HDR EBB of 12 Gy in two fractions during two weeks (6 Gy given once a week) (group 2). However this RCT seemed to be a preliminary report of another trial (<LINK REF="STD-Sur-2004" TYPE="STUDY">Sur 2004</LINK>) that included 65 patients with inoperable, biopsy-proven NSCLC with luminal disease and no prior treatment. All included patients had a Karnofsky score over 60%, and 46% of participants had stage IIIb disease. All patients received EBRT (30 Gy in 10 fractions, 36 Gy in 18 fractions, or 40 Gy in 20 fractions) followed by either EBRT (20 Gy in 10 fractions over two weeks) or EBB (12 Gy in two fractions over two weeks) at a depth of 10 mm.</P>
<P>Finally, in <LINK REF="STD-Mallick-2006" TYPE="STUDY">Mallick 2006</LINK>, 45 patients with previously untreated, inoperable, locally-advanced NSCLC were randomized to three treatment arms: arm A, external radiation to a dose of 30 Gy/10 fr/2 weeks and two sessions of endobronchial brachytherapy; arm B, the same dose of external radiation and a single session of endobronchial brachytherapy 10 Gy at 1 cm and; arm C only a single fraction of brachytherapy to a dose of 15 Gy at 1 cm.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Comparison between different fractionation schedules of palliative HDR EBB</HEADING>
<P>Four RCTs (<LINK REF="STD-Huber-1995" TYPE="STUDY">Huber 1995</LINK>; <LINK REF="STD-Calaguas-1997" TYPE="STUDY">Calaguas 1997</LINK>; <LINK REF="STD-Poellinger-2000" TYPE="STUDY">Poellinger 2000</LINK>; <LINK REF="STD-Mallick-2006" TYPE="STUDY">Mallick 2006</LINK>) compared different fractionation schedules of palliative HDR EBB. Three of the reports were presented as summaries at international lung cancer meetings. Unfortunately we were unable to contact the authors of the articles (<LINK REF="STD-Mallick-2006" TYPE="STUDY">Mallick 2006</LINK>; <LINK REF="STD-Calaguas-1997" TYPE="STUDY">Calaguas 1997</LINK>; <LINK REF="STD-Poellinger-2000" TYPE="STUDY">Poellinger 2000</LINK>) to obtain additional information. Ninety-three participants were recruited in a preliminary analysis of an RCT (<LINK REF="STD-Huber-1995" TYPE="STUDY">Huber 1995</LINK>). They were divided into two groups. The first group received EBB with a total dose of 15.4 Gy delivered in four fractions (3.8 Gy at 10 mm from the source axis at weekly intervals). The second group received EBB with a total dose of 14.4 Gy (fractions of 2 x 7.2 Gy at 10 mm from the source axis at intervals of three weeks). Of the 93 patients included, 44 patients were in group 1: 36 (81.8%) men and 8 (18.2%) women; and 49 were in group 2: 34 (69.4%) men and 15 (30.6%) women. Eighty-nine patients had advanced disease, 65 with NSCLC (31 in group 1; 34 in group 2). The two major histologic types were squamous cell cancer (52.3% and 46.9% respectively) and adenocarcinoma (18.1% and 22.4%). Most patients had undergone pre-treatment: 88.9% in group 1 and 92.7% in group 2, principally with EBRT (group 1, 47.2% mean irradiation dose of 41.8 Gy; group 2, 39% mean irradiation dose of 52.3 Gy) and Nd-YAG laser (33.3% and 46.3%, respectively). More than 40% in each group underwent different combinations of these treatments and the minimum observation time was three months with a median follow-up time of 2.5 years.</P>
<P>The first abstract report (<LINK REF="STD-Calaguas-1997" TYPE="STUDY">Calaguas 1997</LINK>) evaluated the optimal treatment dose of EBB for primary NSCLC as between 5, 7 and 9 Gy (individuals were randomly assigned to each arm) and assessed the clinical response, host performance status scores (not specified), bronchoscopic and radiologic improvements and complications related to the procedure. The number of included patients was 43 and all of them received EBRT prior to EBB.</P>
<P>Another RCT was reported as an abstract (<LINK REF="STD-Poellinger-2000" TYPE="STUDY">Poellinger 2000</LINK>). It investigated different fractionation schedules for palliative EBB of central lung tumors (histologic subtypes and tumor stage were not specified): four times 3.8 Gy (administered at 10 mm depth from the source axis) per week was compared to twice 7.4 Gy at a three-week interval for survival, local control and side effects. One hundred and forty-two patients were randomized to group 1 (60 patients) or group 2 (82 patients). Randomization resulted in an equal distribution for both groups with respect to the age, gender, tumor stage, Karnofsky performance status and histology.</P>
<P>A description of the trial from <LINK REF="STD-Mallick-2006" TYPE="STUDY">Mallick 2006</LINK> was previously provided.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. EBRT versus HDR EBB</HEADING>
<P>We identified three RCTs that compared EBRT with EBB. The RCT from the United Kingdom (UK) (<LINK REF="STD-Stout-2000" TYPE="STUDY">Stout 2000</LINK>) included 99 patients with histologically-confirmed inoperable NSCLC. They were prospectively randomized to receive EBB (a single exposure of 15 Gy at a distance of 10 mm from the iridium source in the bronchus) or EBRT (eight exposures over 10 ± 12 days, a total dose of 30 Gy). Patients were evaluated before treatment; at 4, 8, 16, 26, 38 and 52 weeks; and every 3 months thereafter. The study evaluated performance status, survival, respiratory function and thoracic symptoms assessed either by patients or clinicians. One excluded report (see under <LINK REF="STD-Stout-2000" TYPE="STUDY">Stout 2000</LINK>) gave additional information on the RCT published by Stout et al (<LINK REF="STD-Stout-2000" TYPE="STUDY">Stout 2000</LINK>), concerning the quality of life assessed using the Rotterdam Symptom Checklist and Hospital Anxiety and Depression Scale.</P>
<P>The second trial that compared EBRT with EBB (<LINK REF="STD-Moghissi-1999" TYPE="STUDY">Moghissi 1999</LINK>) included 75 patients with intraluminal microscopically-confirmed NSCLC. Patients were randomized to EBRT (the most frequently used regimen was 17 Gy in two fractions) versus endobronchial treatment. Before randomization, collaborating centres chose whether the endobronchial option should be brachytherapy, laser treatment or cryotherapy, according to which locally available modality was considered most appropriate for the individual. The details of the treatment in both arms were decided by the local clinicians; therefore, there was no homogeneity in the regimens provided. Endobronchial treatment could be given in more than one session, if necessary. Another short report of an RCT, which included 96 patients with inoperable central NSCLC comparing the effects of EBRT versus EBB, seems to be a duplicate of an RCT (see under <LINK REF="STD-Stout-2000" TYPE="STUDY">Stout 2000</LINK>). We could not corroborate that a short study report from Manchester UK, (<LINK REF="STD-Barber-1993" TYPE="STUDY">Barber 1993</LINK>), was an early report of (<LINK REF="STD-Stout-2000" TYPE="STUDY">Stout 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. EBB versus EBB plus chemotherapy</HEADING>
<P>Only one study (<LINK REF="STD-Ferstl-1997" TYPE="STUDY">Ferstl 1997</LINK>) compared EBB with EBB plus chemotherapy. Nineteen patients with advanced central NSCLC, either inoperable or not suitable for EBRT, were randomized into two groups: group 1 received three courses of oral etoposide (150 mg/day over 10 days, 12-day intervals) and EBB (7.2 Gy) on day five of courses 1 and 3; group 2 received EBB alone (2 x 7.2 Gy with a three-week interval).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Combined Nd-YAG laser plus HDR EBB versus Nd-YAG laser alone</HEADING>
<P>Only one study compared Nd-YAG laser plus EBB versus Nd-YAG laser alone (<LINK REF="STD-Chella-2000" TYPE="STUDY">Chella 2000</LINK>). The patients were randomized into two groups: 15 patients in group 1 underwent Nd-YAG laser debulking only; 14 patients in group 2 underwent EBB 15 to 18 days after Nd-YAG laser debulking as outpatients. The dose prescription was 5 Gy at 5 mm, with a total exposition time variable of 10 to 15 minutes.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-10-26 14:47:28 +0200" MODIFIED_BY="[Empty name]">
<P>Overall, few RCTs were judged as having low risk of bias when assessing sequence generation (<LINK REF="STD-Sharma-1998" TYPE="STUDY">Sharma 1998</LINK>; <LINK REF="STD-Moghissi-1999" TYPE="STUDY">Moghissi 1999</LINK>; <LINK REF="STD-Langendijk-2001" TYPE="STUDY">Langendijk 2001</LINK>; <LINK REF="STD-Mallick-2006" TYPE="STUDY">Mallick 2006</LINK>) and allocation concealment (<LINK REF="STD-Moghissi-1999" TYPE="STUDY">Moghissi 1999</LINK>; <LINK REF="STD-Langendijk-2001" TYPE="STUDY">Langendijk 2001</LINK>). All studies but one having unclear risk of bias (<LINK REF="STD-Calaguas-1997" TYPE="STUDY">Calaguas 1997</LINK>) were considered to have low risk of bias for objective outcomes when assessing blinding of participants, personnel and outcome assessment. Detailed information is provided below for each comparison, and in the <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK> table and <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>:</P>
<SUBSECTION>
<HEADING LEVEL="4">1. EBRT versus EBRT in combination with EBB</HEADING>
<P>Some RCTs did not provide information on the methods used for randomization and allocation concealment (<LINK REF="STD-Baas-1994" TYPE="STUDY">Baas 1994</LINK>; <LINK REF="STD-Huber-1997" TYPE="STUDY">Huber 1997</LINK>; <LINK REF="STD-Sharma-1998" TYPE="STUDY">Sharma 1998</LINK>; <LINK REF="STD-Langendijk-2001" TYPE="STUDY">Langendijk 2001</LINK>; <LINK REF="STD-Sur-2004" TYPE="STUDY">Sur 2004</LINK>). However, some authors (<LINK REF="STD-Sharma-1998" TYPE="STUDY">Sharma 1998</LINK>; <LINK REF="STD-Langendijk-2001" TYPE="STUDY">Langendijk 2001</LINK>; <LINK REF="STD-Mallick-2006" TYPE="STUDY">Mallick 2006</LINK>) provided additional information for assessing risk of bias. Two trials described sample size and power calculations (<LINK REF="STD-Huber-1997" TYPE="STUDY">Huber 1997</LINK>; <LINK REF="STD-Langendijk-2001" TYPE="STUDY">Langendijk 2001</LINK>). The German RCT (<LINK REF="STD-Huber-1997" TYPE="STUDY">Huber 1997</LINK>) had seven withdrawals in group 1 and the analysis was based on the remaining 98 patients, using an intention-to-treat analysis.</P>
<P>The study from the Netherlands (<LINK REF="STD-Langendijk-2001" TYPE="STUDY">Langendijk 2001</LINK>) recruited only 59.4% of the required sample. In addition, the RCT had three withdrawals; the analysis was based on the remaining 95 patients. The reasons for exclusion were the presence of distant metastases, cervical carcinoma in the history of one patient and no histologic confirmation of the diagnosis. The abstracts of the other two studies (<LINK REF="STD-Baas-1994" TYPE="STUDY">Baas 1994</LINK>; <LINK REF="STD-Sharma-1998" TYPE="STUDY">Sharma 1998</LINK>) did not report any information regarding withdrawals, group distribution and allocation concealment. The Sur trial (<LINK REF="STD-Sur-2004" TYPE="STUDY">Sur 2004</LINK>) did not report information on sample size or the number of patients evaluated in each arm.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Comparison between different fractionation schedules of palliative HDR EBB</HEADING>
<P>Three RCTs did not provide information on the methods used for randomization and allocation concealment (<LINK REF="STD-Huber-1995" TYPE="STUDY">Huber 1995</LINK>; <LINK REF="STD-Calaguas-1997" TYPE="STUDY">Calaguas 1997</LINK>; <LINK REF="STD-Poellinger-2000" TYPE="STUDY">Poellinger 2000</LINK>). One additional trial provided information on sequence generation while not in allocation concealment methods (<LINK REF="STD-Mallick-2006" TYPE="STUDY">Mallick 2006</LINK>). Similarly none of the studies described sample size and power calculations. No patients were reported to have dropped out or were lost to follow up for the primary endpoint.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. EBRT versus HDR EBB</HEADING>
<P>The included RCTs (<LINK REF="STD-Moghissi-1999" TYPE="STUDY">Moghissi 1999</LINK>; Mogulkoc 2000; <LINK REF="STD-Stout-2000" TYPE="STUDY">Stout 2000</LINK>) did not provide information about the methods of randomization and allocation concealment. Only two RCTs (<LINK REF="STD-Moghissi-1999" TYPE="STUDY">Moghissi 1999</LINK>; <LINK REF="STD-Stout-2000" TYPE="STUDY">Stout 2000</LINK>) provided a description of sample size and a power calculation. In one trial (<LINK REF="STD-Stout-2000" TYPE="STUDY">Stout 2000</LINK>) no patients were reported to have dropped out or were lost to follow up. However, nine participants relapsed after surgery and were excluded from the analysis. In another RCT (<LINK REF="STD-Moghissi-1999" TYPE="STUDY">Moghissi 1999</LINK>) the authors were able to recruit only 18.8% of the required sample. Of the 38 patients randomized to EBRT, 11 (29%) did not receive it and of the 37 patients randomized to EBB, five (14%) did not receive it. Allocation concealment was unclear. In another RCT (<LINK REF="STD-Barber-1993" TYPE="STUDY">Barber 1993</LINK>) there was no information on the methods of randomization, description of sample size, power calculation or allocation concealment. We could not confirm if this report was an early report of <LINK REF="STD-Stout-2000" TYPE="STUDY">Stout 2000</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. EBB versus EBB plus chemotherapy</HEADING>
<P>In one RCT published as an abstract (<LINK REF="STD-Ferstl-1997" TYPE="STUDY">Ferstl 1997</LINK>) there was no information on the method of randomization and no description of the sample size or a power calculation. This trial did not report on withdrawals.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Combined Nd-YAG laser plus HDR EBB versus Nd-YAG laser alone</HEADING>
<P>In the Italian RCT (<LINK REF="STD-Chella-2000" TYPE="STUDY">Chella 2000</LINK>) there was no information on the method of randomization. Sample size and a power calculation were described.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2002-03-13 04:23:09 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. EBRT versus EBRT in combination with EBB</HEADING>
<P>In the German RCT (<LINK REF="STD-Huber-1997" TYPE="STUDY">Huber 1997</LINK>), 42 patients were included in group 1 (EBRT alone) and 56 in group 2 (EBRT plus EBB). The minimum observation time was three months, with a median follow up of 2.5 years. The principal treatment modality before radiotherapy was surgery in seven patients (16.7%) in group 1 and five patients (8.9%) in group 2. The first endoluminal procedure was done in 55 patients (98.2%), while the second irradiation was performed in 25 (44.6%). There was no significant difference in overall survival between groups (28 weeks versus 27 weeks, P = 0.08). Similar results were found when the analysis was done for the patients that received the complete treatment protocol (median survival 43 weeks versus 30 weeks, P = 0.08). However, the study demonstrated some benefit in survival for patients with squamous cell carcinoma (n = 68) adding EBB to EBRT (prolonging life for approximately four months). No significant differences were found between groups for six-month (1 RCT, 96 participants; RR 0.96, 95% CI 0.64 to 1.45) and one-year survival rates (1 RCT, 96 participants; RR 1.31, 95% CI 0.61 to 2.84). After the end of treatment, local control was assessed every three months; minimum advantage in local control with borderline significance (P = 0.052) was found for group 2 as well as some benefits in recurrence-free symptom time for the subgroup of patients with squamous cell histology treated with EBB (P = 0.007, n = 62). The principal cause of death in both groups was tumor growth, with no difference in local compromise and systemic spread between the groups.</P>
<P>In the RCT from the Netherlands (<LINK REF="STD-Langendijk-2001" TYPE="STUDY">Langendijk 2001</LINK>), 83% of the patients randomized to EBRT alone received the planned dose; for the EBRT plus EBB group, 87% received the planned dose of EBRT and two fractions of brachytherapy. Of the 95 patients included, 90 completed a baseline questionnaire to evaluate QOL; compliance to subsequent assessment was 95% at two weeks, 94% at three months, 93% at six months and 83% at 12 months. For patients with atelectasis before radiotherapy, no significant differences were found between groups in radiological re-expansion, using chest X-ray and CT scan (1 RCT, 56 participants; RR 1.64, 95% CI 0.89 to 3.02). In addition, no significant differences were found between groups in the response rate for dyspnea and other respiratory symptoms including cough, hemoptysis, chest pain and pain in the arm or shoulder. Of the primary outcomes, the median survival after EBRT was 8.5 months (95% CI 5.3 to 8.9) and for EBRT plus EBB it was 7 months (95% CI 5.3 to 8.9; P = 0.21). No significant differences were observed between the groups for cause of death; in particular, six patients in the control group died of massive hemoptysis (13%) compared to seven patients treated with EBRT plus EBB (15%). Meta-analysis of three trials (<LINK REF="STD-Huber-1997" TYPE="STUDY">Huber 1997</LINK>; <LINK REF="STD-Langendijk-2001" TYPE="STUDY">Langendijk 2001</LINK>; <LINK REF="STD-Mallick-2006" TYPE="STUDY">Mallick 2006</LINK>) found no significant difference among groups in fatal massive hemoptysis (3 RCT, 236 participants; RR 1.57 95% CI 0.22 to 11.08; I<SUP>2 </SUP>= 57%; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>); it has to be noted that follow-up varied greatly in every RCT.</P>
<P>In another RCT (<LINK REF="STD-Sharma-1998" TYPE="STUDY">Sharma 1998</LINK>) the symptomatic response rates in the EBRT plus EBB group were 65% for cough, 63% for dyspnea, 100% for hemoptysis and 60% for obstructive pneumonia; in the control group the response rates were 15% less for cough and dyspnea, 25% less for hemoptysis and obstructive pneumonia. The objective response rates were also evaluated chest X-ray and bronchoscopic examination. These tests found a response rate of 80% in the study group against 43% in the control group (P &lt; 0.05); the mean duration of symptoms relief was 5.3 months in the EBRT plus EBB group compared to 4.4 months in the EBRT alone group. This study did not evaluate overall survival or time to disease progression. It reported that nine patients in the EBRT alone group developed acute complications which were of mild to moderate severity. Data on the total number of patients allocated to each arm of treatment and analysed were not provided.</P>
<P>The brief abstract of Bass (<LINK REF="STD-Baas-1994" TYPE="STUDY">Baas 1994</LINK>) did not report information on intervention responses but it did describe adverse effects. Of the 43 included patients: 12 received EBRT alone, 12 received HDR EBRT and 15 received photodynamic therapy or EBB, or both. Principal side effects were minor hemoptysis (two patients) and skin photosensitivity.</P>
<P>Another RCT (<LINK REF="STD-Sur-2004" TYPE="STUDY">Sur 2004</LINK>) reported a similar overall survival rate at one year for EBB and EBRT plus EBB (29.4% versus 29.7%; P &gt; 0.05). Median free survival for the control of any symptom was 129 days for EBB plus EBRT versus 77 days for EBRT alone (P = 0.009); in a similar way, the median for dyspnea control was 336 versus 311 days (P = 0.9), 141 versus 133 days (P = 0.05) for cough and 113 versus 127 days (P = 0.28) for chest pain. The study stated that there were no complications due to treatment in either trial arm and the incidence of fatal hemoptysis was comparable between the treatment groups.</P>
<P>In one trial (<LINK REF="STD-Mallick-2006" TYPE="STUDY">Mallick 2006</LINK>) symptomatic response rates (dyspnea, cough, hemoptysis and obstructive pneumonia) and obstruction score were not significantly different when comparing EBRT plus EBB arms with EBB alone, after integrating both EBRT + EBB arms; the symptom incidence rather than the total number of participants were used as denominator to calculate rate ratios. The authors reported that the median time to relapse and the median time to progression of hemoptysis was significantly superior in one EBRT + EBB arm (arm A) compared with EBRT alone.</P>
<P>Meta-analysis of two trials (<LINK REF="STD-Langendijk-2001" TYPE="STUDY">Langendijk 2001</LINK>; <LINK REF="STD-Mallick-2006" TYPE="STUDY">Mallick 2006</LINK>) found no significant difference for dyspnea improvement (125 participants; RR 1.15 95% CI 0.87 to 1.52; I<SUP>2</SUP> = 0%; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>); two arms from one trial (<LINK REF="STD-Mallick-2006" TYPE="STUDY">Mallick 2006</LINK>) receiving brachytherapy at different dose were integrated for meta-analysis. However, it has to be noted that follow-up time in both trials were different.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Comparison between diverse fractionation schedules of palliative HDR EBB</HEADING>
<P>One report in abstract form (<LINK REF="STD-Poellinger-2000" TYPE="STUDY">Poellinger 2000</LINK>) described a significantly superior mean time of local control for the group that received HDR EBB (7.4 Gy twice) (group 2) compared to group 1 (3.8 Gy per week four times): 17 weeks versus 8 weeks, respectively (P = 0.03). Median survival appeared to be longer in group 1 (25 weeks versus 33 weeks) but no level of significance was given. Fatal hemoptysis was significantly less frequent in group 2 compared to group I (1 RCT, 140 participants; RR 1.44, 95% CI 1.44 to 1.82).</P>
<P>In another short report (<LINK REF="STD-Calaguas-1997" TYPE="STUDY">Calaguas 1997</LINK>), the authors reported that there was an improvement in the bronchoscopic, radiologic and clinical findings in patients treated with EBB, without statistically significant differences between the three treatment groups. Complications were seen in 8 of the 43 included cases but without information on the adverse effects and in which treatment groups they occurred. No data were available from the brief report.</P>
<P>Ninety-three patients were included in the German RCT (<LINK REF="STD-Huber-1995" TYPE="STUDY">Huber 1995</LINK>): 44 patients were in the group treated with 3.8 Gy in four fractions (group 1) and 49 were in the group treated with 7.2 Gy in two fractions (group 2). No significant difference was found between groups for the one-year survival rate (1 RCT, 93 participants; RR 0.56, 95% CI 0.21 to 1.50) and the six-month survival rate (1 RCT, 93 participants; RR 0.90, 95% CI 0.49 to 1.65). The mean survival time reached 49 weeks in group 2 while group 1 appeared to have a lower mean survival time (26 weeks) but the difference was not significant. For group 1, the survival chart suggested that patients with squamous cell carcinoma had a small advantage in medial survival (4.75 months versus 2.25 months). In group 2, an increment in median survival in favor of patients with squamous cell cancer was also apparent (8.25 months versus 3 months). The main reason for death was tumor growth, in both groups. There were no significant differences between groups for either local growth or systemic spread.</P>
<P>Fatal hemoptysis was the cause of death in 20% of all cases, with almost equal numbers in both groups (1 RCT, 93 participants; RR 1.56, 95% CI 0.53 to 4.56). Local tumor control was assessed three months after the end of the treatment: 73 patients were evaluated and only 1 patient from group 1 had a complete response. The criteria for partial remission were met by 15 patients (41.6%) in group 1 and 18 patients (48.6%) in group 2 (1 RCT, 73 participants; RR 0.86, 95%CI 0.51 to 1.42). Tumor progression was seen in 15 patients in each group.</P>
<P>In one trial (<LINK REF="STD-Mallick-2006" TYPE="STUDY">Mallick 2006</LINK>) symptomatic response rates (dyspnea <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>, cough <LINK REF="CMP-004.28" TYPE="ANALYSIS">Analysis 4.28</LINK>, hemoptysis <LINK REF="CMP-004.29" TYPE="ANALYSIS">Analysis 4.29</LINK> and obstructive pneumonia <LINK REF="CMP-004.30" TYPE="ANALYSIS">Analysis 4.30</LINK>) and obstruction score were not significantly different when comparing both groups of treatment; the symptom incidence rather than the total number of participants were used as denominator to calculate rate ratios.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. EBRT versus HDR EBB</HEADING>
<P>In one trial (<LINK REF="STD-Stout-2000" TYPE="STUDY">Stout 2000</LINK>), a significant difference was found favoring EBRT in the global palliation response at eight weeks, as assessed by patients (1 RCT, 92 participants; RR 0.72, 95% CI 0.54 to 0.95; Analysis 4.24) and clinicians (1 RCT, 92 participants; RR 0.83, 95% CI 0.69 to 1.00). Among all the symptoms evaluated for response at eight weeks by the clinicians (cough, hemoptysis, breathlessness, chest pain, dysphagia, anorexia, tiredness, nausea and hoarseness) only chest pain (1 RCT, 92 participants; RR 0.76, 95% CI 0.58 to 0.99) and hoarseness (1 RCT, 92 participants; RR 0.76, 95% CI 0.62 to 0.94) showed a significant difference, favoring EBRT. For the same clinical symptoms evaluated at eight weeks by the patients, hemoptysis (1 RCT, 83 participants; RR 0.77, 95% CI 0.62 to 0.97), chest pain (1 RCT, 83 participants; RR 0.55, 95% CI 0.37 to 0.82), anorexia (1 RCT, 83 participants; RR 0.55, 95% CI 0.37 to 0.82; Analysis 4.19) and tiredness (1 RCT, 83 participants; RR 0.46, 95% CI 0.27 to 0.78) showed a significant difference favoring EBRT. At week 16, the authors only reported a significant difference favoring EBRT in the clinicians' assessment of tiredness (P &lt; 0.01).</P>
<P>Fifty-one per cent of 49 patients who were initially treated with EBB subsequently required EBRT; six mostly for persistant and deteriorating symptoms. The median time to re-treatment was 125 days (range 15 to 511 days). Twenty-eight per cent of the patients in the EBRT group had subsequent EBB, at a median time of 304 days, principally for recurrent cough, hemoptysis or breathlessness. No serious late morbidity was encountered. No significant difference was found between groups for massive fatal hemoptysis (1 RCT, 92 participants; RR 1.33, 95% CI 0.32 to 5.63) and all patients had evidence of local tumor recurrence. No differences were recorded in acute morbidity at four weeks based on completion of 38 EBB and 28 EBRT patient questionnaires. EBRT resulted in more resolution of pulmonary collapse and in a modest but statistically significant better overall survival (EBRT 9.56 months versus 8.33 months for EBB; P value not reported). One-year overall survival was 38% for the EBRT group and 22% for the EBB group (1 RCT, 99 participants; RR 0.59, 95% CI 0.31 to 1.11) and 10% versus 2% at two years (1 RCT, 99 participants; RR 0.20, 95% CI 0.02 to 1.68).</P>
<P>In the study by the Medical Research Council Lung Cancer Working Party (<LINK REF="STD-Moghissi-1999" TYPE="STUDY">Moghissi 1999</LINK>), of the 38 patients randomized to EBRT, 11 (29%) did not receive the EBRT; of the 37 patients randomized to EBB, 5 (14%) did not receive the EBB. The most frequently used EBRT regimen was 17 Gy in two fractions (12 patients); iridium-192 was used for all 13 patients who were given brachytherapy. In view of the small number of patients randomized and the high proportion who did not receive their allocated treatment, between treatment comparisons are unlikely to be reliable and are not presented in detail. Using intention-to-treat comparisons the authors reported some significant differences in outcomes. The treatment groups were similar in terms of relief of breathlessness (EBRT 32% versus EBB 28%) and palliation of major thoracic symptoms (EBRT 27% versus EBB 22%). However, improvement in WHO performance status was greater in the EBB group (EBRT 14% versus EBB 38%; difference 24%, 95% CI 8 to 56). During the follow up, the EBB treatment appeared to palliate symptoms better but more patients in this group required interventions for recurrent obstruction. The median overall survival was six months for the EBRT group and five months for the EBB group; the one-year survival rates were not significantly different between groups (26% and 29%, respectively).</P>
<P>In the short report from Barber et al (<LINK REF="STD-Barber-1993" TYPE="STUDY">Barber 1993</LINK>), symptom evaluation at two months showed that hemoptysis was relieved in 100% of patients receiving EBB and in 93% for EBRT. The respective percentages for symptom relief with EBB and EBRT were: 57% and 56% for breathlessness, 41% and 57% for cough, and 58% and 61% for re-expansion of lung collapse. No significant difference was found between groups in the need for re-treatment (1 RCT, 76 participants; RR 1.83, 95% CI 0.75 to 4.45). There was significantly less dysphagia, tiredness, anorexia and nausea at one month with EBB. The median survival for both arms was around 8.5 months. Although data from this study is presented, we could not corroborate if it was an early report of <LINK REF="STD-Stout-2000" TYPE="STUDY">Stout 2000</LINK>.</P>
<P>Meta-analysis of two studies (<LINK REF="STD-Moghissi-1999" TYPE="STUDY">Moghissi 1999</LINK>; <LINK REF="STD-Stout-2000" TYPE="STUDY">Stout 2000</LINK>) found no significant difference in mortality at one year (174 participants; RR 0.78 95% CI 0.49 to 1.24; I<SUP>2 </SUP>=<SUP> </SUP>43%; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>)<B>.</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. EBB versus EBB plus chemotherapy</HEADING>
<P>The only trial making this comparison did not find a significant difference between groups on complete (1 RCT, 19 participants; RR 0.9, 95% CI 0.07 to 12.38) or partial (1 RCT, 19 participants; RR 0.9, 95% CI 0.38 to 2.11) remission of the local tumor at three months (<LINK REF="STD-Ferstl-1997" TYPE="STUDY">Ferstl 1997</LINK>). One-year survival was 17.6% in group 1 (etoposide plus EBB) and 19.5% in group 2 (EBB alone); the mean survival time after treatment was 35 weeks in group 1 and 45 weeks in group 2, with a non-significant difference between the groups. No significant difference was found between treatment groups in deaths due to massive hemoptysis or tracheomediastinal fistula (1 RCT, 19 participants; RR 0.45, 95% CI 0.05 to 4.16); toxicity related to chemotherapy was acceptable (only one patient had hematological toxicity WHO grade 3-4).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Combined Nd-YAG laser plus HDR EBB versus Nd-YAG laser alone</HEADING>
<P>In one trial (<LINK REF="STD-Chella-2000" TYPE="STUDY">Chella 2000</LINK>) a significantly longer symptom-free period was apparent for patients responding to combined Nd-YAG laser and EBB therapies compared to Nd-YAG laser therapy alone (8.5 months versus 2.8 months) (1 RCT, 29 participants; MD 5.30; 95% CI 4.44 to 6.16). Moreover, fewer additional endoscopic treatments were required by the combined treatment group (3 versus 15; P &lt; 0.05). Improvements in lung function tests, including measures of forced expiratory volume, forced vital capacity and Speiser's index, were comparable between treatment groups.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-10-26 14:47:58 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2012-10-26 14:47:58 +0200" MODIFIED_BY="[Empty name]">
<P>A fundamental goal of radiotherapy is to deliver a maximum dose to the tumor while minimizing the dose to surrounding normal tissue. The objective of our review was to address the effects of palliative EBB in increasing survival and controlling thoracic symptoms in patients with advanced NSCLC. We included 13 RCTs, most of which were small and with significant methodological flaws. These studies assessed many different questions and a broad range of treatments, resulting in very limited opportunities to pool data. Conclusions are reported according to the interventions as follows.</P>
<SUBSECTION>
<HEADING LEVEL="4">EBRT versus EBRT in combination with EBB</HEADING>
<P>Overall, there was no evidence of benefit for EBRT in combination with EBB compared to EBRT alone for the primary endpoint of survival or for local control. However, one study (<LINK REF="STD-Huber-1997" TYPE="STUDY">Huber 1997</LINK>) demonstrated some benefit in survival and local control for patients with squamous cell carcinoma. Another study (<LINK REF="STD-Sharma-1998" TYPE="STUDY">Sharma 1998</LINK>) reported a significant difference favoring the EBB group in objective response rates evaluated with chest X-ray and bronchoscopic examination. In addition, no significant differences were found between groups in the response rates for dyspnea and other respiratory symptoms. Only one study found a significant difference for cough, favoring EBB (<LINK REF="STD-Sur-2004" TYPE="STUDY">Sur 2004</LINK>). Fatal hemoptysis was comparable across treatment groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison between different fractionation schedules of palliative HDR EBB</HEADING>
<P>The findings suggest that a variety of fractionation schedules of palliative HDR EBB had similar effects on overall survival (<LINK REF="STD-Huber-1995" TYPE="STUDY">Huber 1995</LINK>; <LINK REF="STD-Poellinger-2000" TYPE="STUDY">Poellinger 2000</LINK>). A schedule of 7.4 Gy in two fractions appeared to be significantly superior to 3.8 Gy in four fractions per week for local control (<LINK REF="STD-Poellinger-2000" TYPE="STUDY">Poellinger 2000</LINK>). However, no significant differences between groups were found in local growth and systemic spread in another trial (<LINK REF="STD-Huber-1995" TYPE="STUDY">Huber 1995</LINK>). Fatal hemoptysis was significantly less frequent with the 7.4 Gy in two fractions schedule group, in one trial (<LINK REF="STD-Poellinger-2000" TYPE="STUDY">Poellinger 2000</LINK>); no significant difference was found in the other trial (<LINK REF="STD-Huber-1995" TYPE="STUDY">Huber 1995</LINK>). No difference on symptom response were found when comparing two doses of 8 Gy x 2 versus a single dose of 10 Gy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">EBRT versus HDR EBB</HEADING>
<P>The comparison between EBRT and HDR EBB in patients with untreated advanced NSCLC favors the use of EBRT. Stout et al (<LINK REF="STD-Stout-2000" TYPE="STUDY">Stout 2000</LINK>) found a relative risk reduction of 28% in the perception of respiratory symptoms by patients after eight weeks of treatment; similarly, the study found a positive trend for the reduction of some symptoms as assessed by clinicians. The main impact of EBRT concerned patients' symptoms. Fifty per cent of patients treated with HDR EBB required EBRT later on, on average four months after the first intervention, while fewer than one third of the patients initially treated with EBRT required HDR EBB, on average 10 months later. The period free of symptoms secondary to bronchial obstruction favors the regular use of EBRT as palliative treatment of advanced NSCLC. Evaluating survival was not one of the aims of this trial, but a post-hoc analysis revealed a survival advantage for EBRT over HDR EBB (relative risk reduction 61%; P = 0.04).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">EBB versus EBB plus chemotherapy</HEADING>
<P>The abstract published by Ferstl et al (<LINK REF="STD-Ferstl-1997" TYPE="STUDY">Ferstl 1997</LINK>) is the only RCT that combined HDR EBB with oral chemotherapy. In spite of the limitations of the patient sample, the authors reported the differences in the response rate and overall survival after one year of follow up. No information was available about the control of respiratory symptoms and adverse effects were only briefly mentioned. There is no information that supports the use of monochemotherapy with etoposide as a radiosensitizer, even when doses of EBB were administered with curative intent. This study does not support the use of a combination of chemotherapy with palliative EBB for advanced NSCLC. The chemotherapy tested in this study cannot be considered as optimal chemotherapy for advanced NSCLC today; new RCTs are needed to evaluate EBRT and EBB in combination with chemotherapy agents, as in esophageal and head and neck cancer (<LINK REF="REF-Dinshaw-1991" TYPE="REFERENCE">Dinshaw 1991</LINK>; <LINK REF="REF-Teo-1999" TYPE="REFERENCE">Teo 1999</LINK>; <LINK REF="REF-Kov_x00e0_cs-2001" TYPE="REFERENCE">Kovàcs 2001</LINK>; <LINK REF="REF-Kumar-2007" TYPE="REFERENCE">Kumar 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Combined Nd-YAG laser plus HDR EBB versus Nd-YAG laser alone</HEADING>
<P>Nd-YAG laser vaporization enables immediate restoration of a viable airway with satisfactory medium-term palliation of obstructive symptoms in advanced NSCLC, probably due to the cytocidal effect deep within the tumor. Endoluminal brachytherapy or photodynamic therapy may be added to prolong patency. Only one RCT (<LINK REF="STD-Chella-2000" TYPE="STUDY">Chella 2000</LINK>) evaluated the feasibility and role of a combined approach; this RCT found a significantly longer symptom-free period and fewer requirements for additional endoscopic treatments in the combined treatment group. Nevertheless, the study did not show any changes in dyspnea, cough or lung function tests. In addition, the sample size was too low to draw conclusions about the benefits of a combination of Nd-YAG laser and EBB.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2002-03-13 04:23:15 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with inoperable lung cancer have a poor prognosis and the therapeutic options to control their symptoms and maintain quality of life are limited (<LINK REF="REF-Lester-2006" TYPE="REFERENCE">Lester 2006</LINK>). Although patients with advanced NSCLC are increasingly being initially treated with chemotherapy (<LINK REF="REF-NSCLC-1995" TYPE="REFERENCE">NSCLC 1995</LINK>), palliative radiation therapy is an important treatment option for patients who have not responded to chemotherapy, have relapsed or have contraindications to potentially toxic drugs (<LINK REF="REF-Lester-2006" TYPE="REFERENCE">Lester 2006</LINK>). One practice guideline developed by the American Brachytherapy Society (ABS) based its recommendations on an extensive literature review, clinical experience, biomathematical modelling and external expert evaluation (<LINK REF="REF-Nag-2001" TYPE="REFERENCE">Nag 2001</LINK>); the guideline included studies involving both low and high dose rate (HDR) EBB, either alone or in combination with EBRT, and focused primarily on indications for treatment and doses. The ABS concluded that palliative EBB should be considered for defined patient populations, particularly those with endobronchial tumors within the lumen that cannot be adequately resected or subjected to further EBRT and are causing persistent respiratory symptoms. Recently, The Program in Evidence-based Care (PEBC) of Cancer Care Ontario (CCO) published a systematic review of palliative EBB in NSCLC (<LINK REF="REF-Ung-2006" TYPE="REFERENCE">Ung 2006</LINK>). This included six RCTs, 18 noncontrolled prospective studies and five retrospective studies with more than 100 patients. Starting with heterogeneous information, this review concluded that EBB in patients with previously untreated, symptomatic endobronchial NSCLC is less effective than EBRT alone. This evidence did not provide conclusive results on whether HDR EBB plus EBRT would offer superior symptom relief over EBRT alone; the authors recommended the use of EBB in patients previously treated with EBRT who become symptomatic with endobronchial obstruction due to recurrent disease.</P>
<P>Although our review included some additional RCTs, we were not able to provide conclusive evidence to recommend the use of EBB plus EBRT, chemotherapy or Nd-YAG laser. Findings from one trial suggest that an EBB schedule of two 7.4 Gy fractions is superior to four fractions of 3.8 Gy per week measuring the mean time of local control and fatal hemoptysis. Some authors have examined the combination of near-simultaneous, HDR brachytherapy with stenting; however no RCTs were found (<LINK REF="REF-Allison-2004" TYPE="REFERENCE">Allison 2004</LINK>). Also a number of endoscopic procedures have been developed and are largely used by chest physicians (<LINK REF="REF-Gompelmann-2011" TYPE="REFERENCE">Gompelmann 2011</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2002-03-13 04:23:17 +0100" MODIFIED_BY="[Empty name]">
<P>The quality of the evidence available for all comparisons was moderate, mainly because there was only one study for each treatment comparison and main results were imprecise in some cases, as reflected in wide confidence intervals. Even though outcome assessment was not blindedin the included RCTs, it is quite unlikely that those circumstances had biased the outcome measures most relevant for patients, especially survival time. However, other outcomes such as response rate could be open to biased assessments. Similarly, the choice of patient made by the recruiter may have been influenced by the lack of allocation concealment.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2002-03-13 04:23:19 +0100" MODIFIED_BY="[Empty name]">
<P>Our search strategy has been comprehensive, including searches of most important clinical trial registers and contact with authors of the studies.Data were extracted and analysed independently by at least two review authors.</P>
</POTENTIAL_BIASES>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-10-29 12:09:26 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-10-29 12:09:26 +0100" MODIFIED_BY="[Empty name]">
<P>From heterogeneous information obtained from several small RCTs, we conclude that EBRT alone is more effective for palliation than EBB alone. We were not able to provide conclusive evidence to recommend EBB combination with EBRT, chemotherapy or Nd-YAG laser. For patients previously treated by EBRT and who are symptomatic from recurrent disease because of endobronchial central obstruction, EBB should be considered in selected cases.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2002-03-13 04:23:21 +0100" MODIFIED_BY="[Empty name]">
<P>High-quality research is needed to examine the real role of EBB in the palliative care of advanced NSCLC. It is important to determine the best dose and fractionation schedule, and technical matters like distances to tissue and duration of the intervention. The new RCTs should explore the utility of a combination of EBB with Nd-YAG laser, diverse schemes of EBRT, photodynamic therapy and chemotherapy following some established outlines for chemoradiation in locally advanced disease. In addition, RCTs comparing EBB with other endoscopic procedures (i.e. stenting) should be evaluated in patients receiving optimal treatment for their NSCLC.       </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2002-03-13 04:23:22 +0100" MODIFIED_BY="[Empty name]">
<P>We thank the Cochrane Lung Cancer Group for their assistance.The authors acknowledge the key contribution to Edgar Ospina, Andrés Yepes and Vanessa Ospina in the design and conduct of the first published version of the review. We also wish to acknowledge Desiree M. West, consumer of the Cochrane Lung Cancer Group, for her revisions.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2002-03-13 04:23:25 +0100" MODIFIED_BY="[Empty name]">
<P>Ludovic Reveiz has contributed to this systematic review in a personal capacity and during his spare time. His views do not necessarily reflect those of his employers. The Pan American Health Organization does not assume responsibility for the statements contained therein.</P>
<P>Andres Felipe Cardona received a research stipend from Pfizer S.A., Productos Roche S.A and Boehringer Ingelheim; his research was not related to the interventions evaluated in this review.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-10-29 06:53:13 +0100" MODIFIED_BY="[Empty name]">
<P>Ludovic Reveiz and Andrés Felipe Cardona initiated, designed and conducted the study and wrote the protocol and the final text in all the versions of this review. In this current version Ludovic Reveiz and José-Ramón Rueda screened the new references found in the literature search, extracted data from included studies and evaluated their risk of bias.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2002-03-13 05:28:50 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2002-03-13 05:28:50 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2002-03-13 05:28:40 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Baas-1994" MODIFIED="2012-10-16 10:03:16 +0200" MODIFIED_BY="Megan J Prictor" NAME="Baas 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-10-16 10:03:16 +0200" MODIFIED_BY="Megan J Prictor" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baas P</AU>
<TI>Photodynamic therapy and/or endobronchial irradiation as pretreatment in external radiation therapy for patients with inoperable non-small cell lung cancer: an interim analysis</TI>
<SO>European Journal of Cancer</SO>
<YR>1994</YR>
<VL>30</VL>
<NO>Suppl 1</NO>
<PG>33</PG>
<IDENTIFIERS MODIFIED="2012-10-16 10:03:16 +0200" MODIFIED_BY="Megan J Prictor">
<IDENTIFIER MODIFIED="2012-10-16 10:03:16 +0200" MODIFIED_BY="Megan J Prictor" TYPE="DOI" VALUE="10.1016/0959-8049(94)90812-5"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barber-1993" MODIFIED="2012-10-16 10:03:29 +0200" MODIFIED_BY="Megan J Prictor" NAME="Barber 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-10-16 10:03:29 +0200" MODIFIED_BY="Megan J Prictor" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barber P, Stout R, Burt P</AU>
<TI>Radiotherapy for inoperable lung cancer: a randomized comparison of fractionated luminal radiotherapy (ILT)</TI>
<SO>European Respiratory Journal</SO>
<YR>1993</YR>
<VL>6</VL>
<NO>Suppl 17</NO>
<PG>395</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Calaguas-1997" MODIFIED="2012-10-16 10:04:03 +0200" MODIFIED_BY="Megan J Prictor" NAME="Calaguas 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-10-16 10:04:03 +0200" MODIFIED_BY="Megan J Prictor" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calaguas MJC, Barretto LB, Leonardia RR</AU>
<TI>High dose rate endobronchial brachytherapy for bronchogenic carcinoma: The lung center of the Philippines experience: A preliminary report</TI>
<SO>Lung Cancer</SO>
<YR>1997</YR>
<VL>18</VL>
<NO>Suppl 1</NO>
<PG>131</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chella-2000" NAME="Chella 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chella A, Ambrogi MC, Ribechini A, Mussi A, Fabrini MG, Silvano G, et al</AU>
<TI>Combined Nd-YAG laser/HDR brachytherapy versus Nd-YAG laser only in malignant central airway involvement: a prospective randomized study</TI>
<SO>Lung Cancer</SO>
<YR>2000</YR>
<VL>27</VL>
<NO>3</NO>
<PG>169-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferstl-1997" MODIFIED="2002-03-13 04:25:19 +0100" MODIFIED_BY="[Empty name]" NAME="Ferstl 1997" YEAR="1997">
<REFERENCE MODIFIED="2002-03-13 04:25:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferstl A, Fischer R, Hautmann H, Pollinger B, Hausinger K, Huber RM</AU>
<TI>Simultaneous chemotherapy and high dose rate brachytherapy (HDRBT) in the treatment of locally advanced non-small cell lung cancer</TI>
<SO>European Respiratory Journal</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>Suppl 25</NO>
<PG>198S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huber-1995" MODIFIED="2002-03-13 05:21:13 +0100" MODIFIED_BY="[Empty name]" NAME="Huber 1995" YEAR="1995">
<REFERENCE MODIFIED="2002-03-13 04:25:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huber RM, Fischer R, Hautmann H, Pollinger B, Wendt T, Muller-Wening D, et al</AU>
<TI>Palliative endobronchial brachytherapy for central lung tumors. A prospective, randomized comparison of two fractionation schedules</TI>
<SO>Chest</SO>
<YR>1995</YR>
<VL>107</VL>
<NO>2</NO>
<PG>463-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huber-1997" MODIFIED="2002-03-13 05:21:13 +0100" MODIFIED_BY="[Empty name]" NAME="Huber 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huber RM, Fischer R, Hautmann H, Pollinger B, Haussinger K, Wendt T</AU>
<TI>Does additional brachytherapy improve the effect of external irradiation? A prospective, randomized study in central lung tumors</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1997</YR>
<VL>38</VL>
<NO>3</NO>
<PG>533-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2002-03-13 05:21:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huber RM, Wendt T, Pforte A, Heinz S, Hautmann H, Gassner F, et al</AU>
<TI>Additional effect of high dose rate endoluminal irradiation (AL) in patients with central lung tumours: preliminary results of a randomized study</TI>
<SO>European Respiratory Journal</SO>
<YR>1990</YR>
<VL>3</VL>
<NO>Suppl 10</NO>
<PG>221</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Langendijk-2001" MODIFIED="2012-05-25 12:16:00 +0200" MODIFIED_BY="[Empty name]" NAME="Langendijk 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Langendijk H, de Jong J, Tjwa M, Muller M, ten Velde G, Aaronson N, et al</AU>
<TI>External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study</TI>
<SO>Radiotherapy and Oncology</SO>
<YR>2001</YR>
<VL>58</VL>
<NO>3</NO>
<PG>257-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Mallick-2006" MODIFIED="2012-05-24 11:43:56 +0200" MODIFIED_BY="[Empty name]" NAME="Mallick 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-05-22 11:57:13 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mallick I, Sharma SC, Behera D, Ghoshal S, Oinam AS</AU>
<TI>Optimization of dose and fractionation of endobronchial brachytherapy with or without external radiation in the palliative management of non-small cell lung cancer: a prospective randomized study</TI>
<SO>Journal of Cancer Research and Therapeutics</SO>
<YR>2006</YR>
<VL>2</VL>
<NO>3</NO>
<PG>119-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moghissi-1999" NAME="Moghissi 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moghissi K, Bond MG, Sambrook RJ, Stephens RJ, Hopwood P, Girling DJ</AU>
<TI>Treatment of endotracheal or endobronchial obstruction by non-small cell lung cancer: lack of patients in an MRC randomized trial leaves key questions unanswered. Medical Research Council Lung Cancer Working Party</TI>
<SO>Clinical Oncology</SO>
<YR>1999</YR>
<VL>11</VL>
<PG>3179-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poellinger-2000" MODIFIED="2002-03-13 05:19:07 +0100" MODIFIED_BY="[Empty name]" NAME="Poellinger 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poellinger B, Huber RM, Fischer R, Hautmann H, Siefert A, Duehmke E</AU>
<TI>High-dose rate brachytherapy (HDR-BT): a prospective randomized trial of two fractionation schedules in the palliative treatment of central lung tumours</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2000</YR>
<VL>48</VL>
<NO>3 Suppl 1</NO>
<PG>244</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2002-03-13 05:19:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pollinger B, Huber RM, Fischer R, Siefert A, Busch M, Kiszel Z, et al</AU>
<TI>HDR-brachytherapy und external irradiation by central inoperable lung tumours: prospective randomised comparison</TI>
<SO>Strahlentherapie und Onkologie</SO>
<YR>1997</YR>
<VL>173</VL>
<NO>11</NO>
<PG>572</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2002-03-13 05:19:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pollinger B, Huber RM, Fischer R, Siefert A, Kiszel Z, Busch M, et al</AU>
<TI>Prospective randomised trial on the role of HDR-brachytherapy in addition to external beam radiotherapy for central bronchial carcinoma</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1996</YR>
<VL>36</VL>
<NO>Suppl 1</NO>
<PG>208</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sharma-1998" MODIFIED="2012-10-16 10:06:25 +0200" MODIFIED_BY="[Empty name]" NAME="Sharma 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-10-16 10:06:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma SC, Beriwal S, Behra D, Gupta D, Singh DP, Goyal R</AU>
<TI>Prospective comparative study of external radiation plus HDR endobronchial brachytherapy versus external radiation alone in the palliative treatment of Bronchogenic Carcinoma</TI>
<SO>Radiotherapy and Oncology</SO>
<YR>1998</YR>
<VL>48</VL>
<NO>Suppl 1</NO>
<PG>210</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stout-2000" MODIFIED="2002-03-13 05:28:40 +0100" MODIFIED_BY="[Empty name]" NAME="Stout 2000" YEAR="2000">
<REFERENCE MODIFIED="2002-03-13 05:26:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hopwood P, R Swindell, P Burt, R. Stout, P Barber</AU>
<TI>Clinically relevant quality of life outcomes in the first UK randomised trial of endobronchial brachytherapy (EBT) versus external beam radiotherapy (XRT) in patients with inoperable non-small cell cancer (NSCLC)</TI>
<SO>Lung Cancer</SO>
<YR>1997</YR>
<VL>18</VL>
<NO>Suppl 1</NO>
<PG>130</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2002-03-13 05:28:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mogulkoc N, Barber P, Burt P, Hopwood P, Hodgetts J, Lomax L, et al</AU>
<TI>A randomised comparison of the effect of external beam radiotherapy (ERT) and intraluminal radiotherapy (ILT) on pulmonary function in unresectable non-small cell lung cancer (NSCLC)</TI>
<SO>European Respiratory Journal</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>Suppl 31</NO>
<PG>48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stout R, Barber P, Burt P, Hopwood P, Swindell R, Hodgetts J, et al</AU>
<TI>Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) vs. external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer</TI>
<SO>Radiotherapy and Oncology</SO>
<YR>2000</YR>
<VL>56</VL>
<NO>3</NO>
<PG>323-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sur-2004" MODIFIED="2002-03-13 05:14:19 +0100" MODIFIED_BY="[Empty name]" NAME="Sur 2004" YEAR="2004">
<REFERENCE MODIFIED="2002-03-13 05:14:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sur R, Ahmed SN, Donde B, Morar R, Mohamed G, Sur M, et al</AU>
<TI>Brachytherapy boost vs teletherapy boost in palliation of symptomatic, locally advanced non-small cell lung cancer: preliminary analysis of a randomized, prospective study</TI>
<SO>Brachytherapy International</SO>
<YR>2001</YR>
<VL>17</VL>
<NO>4</NO>
<PG>309-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-16 10:06:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sur R, Donde B, Mohuiddin M, Ahmed N, Pacella J, Mohamed G, et al</AU>
<TI>Randomized prospective study on the role of high dose rate intraluminal brachytherapy (HDRILBT) in palliation of symptoms in advanced non small cell lung cancer (NSCLC) treated with radiation alone</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2004</YR>
<VL>60</VL>
<NO>1 Suppl 1</NO>
<PG>A127</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2002-03-13 05:28:50 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anacak-2001" NAME="Anacak 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anacak Y, Mogulkoc N, Ozkok S, Goksel T, Haydaroglu A, Bayindir U</AU>
<TI>High dose rate endobronchial brachytherapy in combination with external beam radiotherapy for stage III non-small cell lung cancer</TI>
<SO>Lung Cancer</SO>
<YR>2001</YR>
<VL>34</VL>
<NO>2</NO>
<PG>253-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bedwinek-1992" NAME="Bedwinek 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bedwinek J, Petty A, Bruton C, Sofield J, Lee L</AU>
<TI>The use of high dose rate endobronchial brachytherapy to palliate symptomatic endobronchial recurrence of previously irradiated bronchogenic carcinoma</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1992</YR>
<VL>22</VL>
<NO>1</NO>
<PG>23-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burt-1990" NAME="Burt 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burt PA, O'Driscoll BR, Notley HM, Barber PV, Stout R</AU>
<TI>Intraluminal irradiation for the palliation of lung cancer with the high dose rate micro-Selectron</TI>
<SO>Thorax</SO>
<YR>1990</YR>
<VL>45</VL>
<NO>10</NO>
<PG>765-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delclos-1996" NAME="Delclos 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delclos ME, Komaki R, Morice RC, Allen PK, Davis M, Garden A</AU>
<TI>Endobronchial brachytherapy with high-dose-rate remote afterloading for recurrent endobronchial lesions</TI>
<SO>Radiology</SO>
<YR>1996</YR>
<VL>201</VL>
<NO>1</NO>
<PG>279-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Escobar_x002d_Sacristan-2004" MODIFIED="2012-10-16 10:07:34 +0200" MODIFIED_BY="Megan J Prictor" NAME="Escobar-Sacristan 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Escobar-Sacristan JA, Granda-Orive JI, Gutierrez JT, Delgado JM, Rodero BA, Saez VR</AU>
<TI>Endobronchial brachytherapy in the treatment of malignant lung tumours</TI>
<SO>European Respiratory Journal</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>3</NO>
<PG>348-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fass-1990" MODIFIED="2012-10-16 10:14:07 +0200" MODIFIED_BY="Megan J Prictor" NAME="Fass 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-10-16 10:14:07 +0200" MODIFIED_BY="Megan J Prictor" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fass DE, Armstrong J, Harrison LB</AU>
<TI>Fractionated high dose rate endobronchial treatment for recurrent lung cancer</TI>
<SO>Endocurie Hyperther Oncol</SO>
<YR>1990</YR>
<VL>6</VL>
<PG>211-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernando-2011a" MODIFIED="2002-03-13 04:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Fernando 2011a" YEAR="">
<REFERENCE MODIFIED="2002-03-13 04:26:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernando HC, Landreneau RJ, Mandrekar SJ, Hillman SL, Nichols FC, Meyers B, et al</AU>
<TI>Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non-small cell lung cancer: results from a multicenter phase III study</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>2011</YR>
<VL>142</VL>
<NO>5</NO>
<PG>1143-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernando-2011b" MODIFIED="2002-03-13 04:27:26 +0100" MODIFIED_BY="[Empty name]" NAME="Fernando 2011b" YEAR="">
<REFERENCE MODIFIED="2002-03-13 04:27:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernando HC, Landreneau RJ, Mandrekar SJ, Hillman SL, Nichols FC, Meyers B, et al</AU>
<TI>The impact of adjuvant brachytherapy with sublobar resection on pulmonary function and dyspnea in high-risk patients with operable disease: preliminary results from the American College of Surgeons Oncology Group Z4032 trial</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>2011</YR>
<VL>142</VL>
<NO>3</NO>
<PG>554-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freitag-2004" NAME="Freitag 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freitag L, Ernst A, Thomas M, Prenzel R, Wahlers B, Macha HN</AU>
<TI>Sequential photodynamic therapy (PDT) and high dose brachytherapy for endobronchial tumour control in patients with limited bronchogenic carcinoma</TI>
<SO>Thorax</SO>
<YR>2005</YR>
<VL>59</VL>
<NO>9</NO>
<PG>790-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gauwitz-1992" MODIFIED="2012-10-16 10:18:16 +0200" MODIFIED_BY="Megan J Prictor" NAME="Gauwitz 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-10-16 10:18:16 +0200" MODIFIED_BY="Megan J Prictor" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gauwitz M, Ellerbroek N, Komaki R, Putnam JB Jr, Ryan MB, DeCaro L, et al</AU>
<TI>High dose endobronchial irradiation in recurrent bronchogenic carcinoma</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1992</YR>
<VL>23</VL>
<NO>2</NO>
<PG>397-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gejerman-2002" NAME="Gejerman 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gejerman G, Mullokandov EA, Bagiella E, Blaivas A, Beitler JJ</AU>
<TI>Endobronchial brachytherapy and external-beam radiotherapy in patients with endobronchial obstruction and extrabronchial extension</TI>
<SO>Brachytherapy</SO>
<YR>2002</YR>
<VL>1</VL>
<NO>4</NO>
<PG>204-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldman-1993" NAME="Goldman 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldman JM, Bulman AS, Rathmell AJ, Carey BM, Muers MF, Joslin CAF</AU>
<TI>Physiological effect of endobronchial radiotherapy in patients with major airway occlusion by carcinoma</TI>
<SO>Thorax</SO>
<YR>1993</YR>
<VL>48</VL>
<NO>2</NO>
<PG>110-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hernandez-1996" NAME="Hernandez 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hernandez P, Gursahaney A, Roman T, Schwartzman K, Donath D, Cosio MG, et al</AU>
<TI>High dose rate brachytherapy for the local control of endobronchial carcinoma following external irradiation</TI>
<SO>Thorax</SO>
<YR>1996</YR>
<VL>51</VL>
<NO>4</NO>
<PG>354-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mallick-2007" MODIFIED="2012-05-22 12:02:03 +0200" MODIFIED_BY="[Empty name]" NAME="Mallick 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-05-22 12:02:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mallick I, Sharma SC, Behera D</AU>
<TI>Endobronchial brachytherapy for symptom palliation in non-small cell lung cancer--analysis of symptom response, endoscopic improvement and quality of life</TI>
<SO>Lung Cancer</SO>
<YR>2007</YR>
<VL>55</VL>
<NO>3</NO>
<PG>313-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mehta-1992" NAME="Mehta 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mehta M, Petereit D, Chosy L, Harmon M, Fowler J, Shahabi S, et al</AU>
<TI>Sequential comparison of low dose rate and hyperfractionated high dose rate endobronchial radiation for malignant airway occlusion</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1992</YR>
<VL>23</VL>
<NO>1</NO>
<PG>133-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ofiara-1997" NAME="Ofiara 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ofiara L, Roman T, Schwartzman K, Levy RD</AU>
<TI>Local determinants of response to endobronchial high-dose rate brachytherapy in bronchogenic carcinoma</TI>
<SO>Chest</SO>
<YR>1997</YR>
<VL>112</VL>
<NO>4</NO>
<PG>946-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ornadel-1997" NAME="Ornadel 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ornadel D, Duchesne G, Wall P, Ng A, Hetzel M</AU>
<TI>Defining the roles of high dose rate endobronchial brachytherapy and laser resection for recurrent bronchial malignancy</TI>
<SO>Lung Cancer</SO>
<YR>1997</YR>
<VL>16</VL>
<NO>2-3</NO>
<PG>203-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perol-1997" NAME="Perol 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perol M, Caliandro R, Pommier P, Malet C, Montbarbon X, Carrie C, et al</AU>
<TI>Curative irradiation of limited endobronchial carcinomas with high-dose rate brachytherapy. Results of a pilot study</TI>
<SO>Chest</SO>
<YR>1997</YR>
<VL>111</VL>
<NO>5</NO>
<PG>1417-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Speiser-1993a" MODIFIED="2012-10-16 11:31:37 +0200" MODIFIED_BY="Megan J Prictor" NAME="Speiser 1993a" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Speiser BL, Spratling L</AU>
<TI>Radiation bronchitis and stenosis secondary to high dose rate endobronchial irradiation</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1993</YR>
<VL>25</VL>
<PG>589-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Speiser-1993b" MODIFIED="2012-10-16 11:31:42 +0200" MODIFIED_BY="Megan J Prictor" NAME="Speiser 1993b" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Speiser BL, Spratling L</AU>
<TI>Remote afterloading brachytherapy for the local control of endobronchial carcinoma</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1993</YR>
<VL>25</VL>
<NO>4</NO>
<PG>579-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutedja-1992" NAME="Sutedja 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sutedja G, Baris G, Schaake-Koning C, van Zandwijk N</AU>
<TI>High dose rate brachytherapy in patients with local recurrences after radiotherapy of non-small cell lung cancer</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1992</YR>
<VL>24</VL>
<NO>3</NO>
<PG>551-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tr_x00e9_daniel-1994" NAME="Trédaniel 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tredaniel J, Hennequin C, Zalcm.an G, Walter S, Homasson JP, Maylin C, et al</AU>
<TI>Prolonged survival after high-dose rate endobronchial radiation for malignant airway obstruction</TI>
<SO>Chest</SO>
<YR>1994</YR>
<VL>105</VL>
<NO>3</NO>
<PG>767-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-06-27 17:46:21 +0200" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2012-06-22 08:58:34 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Brachy-2011" MODIFIED="2012-06-12 09:29:33 +0200" MODIFIED_BY="[Empty name]" NAME="Brachy 2011" YEAR="2011">
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2002-03-13 04:32:45 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2002-03-13 04:32:45 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ACS-2010" MODIFIED="2002-03-13 04:30:28 +0100" MODIFIED_BY="[Empty name]" NAME="ACS 2010" TYPE="OTHER">
<AU>American Cancer Society</AU>
<TI>Cancer Facts &amp; Figures 2010</TI>
<SO>Available at http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-and-figures-201</SO>
<VL>Accessed December, 2011</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allison-2004" MODIFIED="2002-03-13 04:30:39 +0100" MODIFIED_BY="[Empty name]" NAME="Allison 2004" TYPE="JOURNAL_ARTICLE">
<AU>Allison R, Sibata C, Sarma K, Childs CJ, Downie GH</AU>
<TI>High-dose-rate brachytherapy in combination with stenting offers a rapid and statistically significant improvement in quality of life for patients with endobronchial recurrence
</TI>
<SO>Cancer Journal</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>6</NO>
<PG>368-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Becket-1993" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Becket 1993" TYPE="JOURNAL_ARTICLE">
<AU>Becket WS</AU>
<TI>Epidemiology and etiology of lung cancer</TI>
<SO>Clinics in Chest Medicine</SO>
<YR>1993</YR>
<VL>14</VL>
<PG>1-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boyle-2000" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Boyle 2000" TYPE="BOOK_SECTION">
<AU>Boyle P, Gandini S, Gray N</AU>
<TI>Epidemiology of lung cancer: a century of great success and ignominious failure</TI>
<SO>IASLC Textbook of Lung Cancer</SO>
<YR>2000</YR>
<PG>13-26</PG>
<ED>Hansen H</ED>
<PB>Martin Dunitz</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burt-1987" MODIFIED="2002-03-13 04:31:12 +0100" MODIFIED_BY="[Empty name]" NAME="Burt 1987" TYPE="JOURNAL_ARTICLE">
<AU>Burt ME, Pomerantz AH, Bains MS, McCormack PM, Kaiser LR, Hilaris BS, et al</AU>
<TI>Results of surgical treatment of stage III lung cancer invading the mediastinum</TI>
<SO>The Surgical Clinics of North America</SO>
<YR>1987</YR>
<VL>67</VL>
<NO>5</NO>
<PG>987-1000</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Castro-1999" MODIFIED="2002-03-13 04:31:25 +0100" MODIFIED_BY="[Empty name]" NAME="Castro 1999" TYPE="JOURNAL_ARTICLE">
<AU>Castro AA, Clark OAC, Atallah AN</AU>
<TI>Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature Database (LILACS database): update</TI>
<SO>Sao Paulo Medical Journal</SO>
<YR>1999</YR>
<VL>117</VL>
<PG>3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-1994" MODIFIED="2002-03-13 04:31:49 +0100" MODIFIED_BY="[Empty name]" NAME="Chang 1994" TYPE="JOURNAL_ARTICLE">
<AU>Chang LF, Horvath J, Peyton W, Ling SS</AU>
<TI>High dose rate afterloading intraluminal brachytherapy in malignant airway obstruction of lung cancer</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1994</YR>
<VL>28</VL>
<NO>3</NO>
<PG>589-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dinshaw-1991" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Dinshaw 1991" TYPE="JOURNAL_ARTICLE">
<AU>Dinshaw KA, Sharma V, Pendse AM, Telang CS, Vege SS, Malliat MK, et al</AU>
<TI>The role of intraluminal radiotherapy and concurrent 5-fluorouracil infusion in the management of carcinoma esophagus: a pilot study</TI>
<SO>Journal of Surgical Oncology</SO>
<YR>1991</YR>
<VL>47</VL>
<NO>3</NO>
<PG>155-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Emami-1997" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Emami 1997" TYPE="JOURNAL_ARTICLE">
<AU>Emami B, Kaiser L, Simpson J, Shapiro S, Roper C, Lockett MA</AU>
<TI>Postoperative radiation therapy in non-small cell lung cancer</TI>
<SO>American Journal of Clinical Oncology</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>5</NO>
<PG>441-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Globocan-IARC-2002" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Globocan IARC 2002" TYPE="OTHER">
<AU>Ferlay J, Bray F, Pisari P, Parkin DM</AU>
<TI>Globocan 2002. Cancer incidence, mortality and prevalence worldwide</TI>
<SO>www-dep.iarc.fr/dataava/infodata.htm</SO>
<YR>(accessed December 11 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gompelmann-2011" MODIFIED="2012-10-03 14:51:07 +0200" MODIFIED_BY="[Empty name]" NAME="Gompelmann 2011" TYPE="JOURNAL_ARTICLE">
<AU>Gompelmann D, Eberhardt R, Herth FJ</AU>
<TI>Advanced malignant lung disease: what the specialist can offer</TI>
<SO>Respiration</SO>
<YR>2011</YR>
<VL>82</VL>
<NO>2</NO>
<PG>111-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-10-09 11:29:28 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hilaris-1994" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Hilaris 1994" TYPE="JOURNAL_ARTICLE">
<AU>Hilaris BS</AU>
<TI>Lung brachytherapy. An overview and current indications</TI>
<SO>Chest Surgery Clinics of North America</SO>
<YR>1994</YR>
<VL>4</VL>
<NO>1</NO>
<PG>45-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kov_x00e0_cs-2001" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Kovàcs 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kovàcs G; RTOG-9207-Studie</AU>
<TI>Percutaneous radiotherapy plus brachytherapy and concurrent chemotherapy for patients with localized esophageal carcinoma - Radiation Oncology Group Study 9207</TI>
<SO>Strahlenther Onkologie</SO>
<YR>2001</YR>
<VL>177</VL>
<NO>5</NO>
<PG>269-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kumar-2007" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Kumar 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kumar S, Dimri K, Khurana R, Rastogi N, Das KJ, Lal P</AU>
<TI>A randomised trial of radiotherapy compared with cisplatin chemo-radiotherapy in patients with unresectable squamous cell cancer of the esophagus</TI>
<SO>Radiotherapy and Oncology</SO>
<YR>2007</YR>
<VL>83</VL>
<NO>2</NO>
<PG>139-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lester-2006" MODIFIED="2012-10-09 11:29:09 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Lester 2006" TYPE="COCHRANE_REVIEW">
<AU>Lester JF, Macbeth FR, Toy E, Coles B</AU>
<TI>Palliative radiotherapy regimens for non-small cell lung cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-10-09 11:29:09 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-10-09 11:29:09 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002143.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Maher-1993" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Maher 1993" TYPE="JOURNAL_ARTICLE">
<AU>Maher EJ, Timothy A, Squire CJ, Goodman A, Karp SJ, Paine CH, et al</AU>
<TI>Audit: the use of radiotherapy for NSCLC in the UK</TI>
<SO>Clinical Oncology</SO>
<YR>1993</YR>
<VL>5</VL>
<NO>2</NO>
<PG>72-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nag-2001" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Nag 2001" TYPE="JOURNAL_ARTICLE">
<AU>Nag S, Kelly JF, Horton JL, Komaki R, Nori D</AU>
<TI>Brachytherapy for carcinoma of the lung. Recommendations from the American Brachytherapy Society</TI>
<SO>Oncology (Huntington)</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>3</NO>
<PG>371-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NSCLC-1995" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="NSCLC 1995" TYPE="JOURNAL_ARTICLE">
<AU>Non-small cell Lung Cancer Collaborative Group</AU>
<TI>Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>311</VL>
<PG>899-909</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paradelo-1992" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Paradelo 1992" TYPE="JOURNAL_ARTICLE">
<AU>Paradelo JC, MJ Waxman, BJ Throne, TA Beller, WJ Kopecky</AU>
<TI>Endobronchial irradiation with 192Ir in the treatment of malignant endobronchial obstruction</TI>
<SO>Chest</SO>
<YR>1992</YR>
<VL>102</VL>
<NO>4</NO>
<PG>1072-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perez-1992" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Perez 1992" TYPE="BOOK">
<AU>Perez CA, Brady LW, editors</AU>
<SO>Principles and Practice of Radiation Oncology</SO>
<YR>1992:50-63;114-23</YR>
<EN>2nd</EN>
<PB>JB Lippincott Co</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rodrigues-2012" MODIFIED="2002-03-13 04:32:20 +0100" MODIFIED_BY="[Empty name]" NAME="Rodrigues 2012" TYPE="JOURNAL_ARTICLE">
<AU>Rodrigues G, Macbeth F, Burmeister B, Kelly KL, Bezjak A, Langer C, et al</AU>
<TI>Consensus statement on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control</TI>
<SO>Clinical Lung Cancer</SO>
<YR>2012</YR>
<VL>13</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schray-1988" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Schray 1988" TYPE="JOURNAL_ARTICLE">
<AU>Schray MF, McDougall JC, Martinez A, Cortese DA, Brutinel WM</AU>
<TI>Management of malignant airway compromise with laser and low dose rate brachytherapy: the Mayo Clinic experience</TI>
<SO>Chest</SO>
<YR>1988</YR>
<VL>93</VL>
<NO>2</NO>
<PG>264-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seagren-1985" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Seagren 1985" TYPE="JOURNAL_ARTICLE">
<AU>Seagren SL, Harrell JH, Horn RA</AU>
<TI>High dose rate intraluminal irradiation in recurrent endobronchial carcinoma</TI>
<SO>Chest</SO>
<YR>1985</YR>
<VL>88</VL>
<NO>6</NO>
<PG>810-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shaw-1993" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Shaw 1993" TYPE="JOURNAL_ARTICLE">
<AU>Shaw EG, Bonner JA, Foote RL, Martenson JA Jr, Frytak S, Deschamps C, et al</AU>
<TI>Role of radiation therapy in the management of lung cancer</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>1993</YR>
<VL>68</VL>
<NO>6</NO>
<PG>593-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sirz_x00e9_n-2003" MODIFIED="2002-03-13 04:32:45 +0100" MODIFIED_BY="[Empty name]" NAME="Sirzén 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sirzén F, Kjellén E, Sörenson S, Cavallin-Stahl E</AU>
<TI>A systematic overview of radiation therapy effects in non-small cell lung cancer</TI>
<SO>Acta Oncologica</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>5-6</NO>
<PG>493-515</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Speiser-1999" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Speiser 1999" TYPE="JOURNAL_ARTICLE">
<AU>Speiser BL</AU>
<TI>Brachytherapy in the treatment of thoracic tumors. Lung and esophageal</TI>
<SO>Hematology/Oncology Clinics of North America</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>3</NO>
<PG>609-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sutherland-2012" MODIFIED="2012-10-16 10:34:00 +0200" MODIFIED_BY="[Empty name]" NAME="Sutherland 2012" TYPE="JOURNAL_ARTICLE">
<AU>Sutherland JG, Furutani KM, Garces YI, Thomson RM</AU>
<TI>Model-based dose calculations for (125)I lung brachytherapy</TI>
<SO>Med Phys</SO>
<YR>2012</YR>
<VL>39</VL>
<NO>7</NO>
<PG>4365-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Teo-1999" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Teo 1999" TYPE="JOURNAL_ARTICLE">
<AU>Teo PM, Chan AT, Lee WY, Leung TW, Johnson PJ</AU>
<TI>Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1999</YR>
<VL>43</VL>
<NO>2</NO>
<PG>261-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ung-2006" MODIFIED="2008-09-18 23:27:48 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Ung 2006" TYPE="JOURNAL_ARTICLE">
<AU>Ung YC, Yu E, Falkson C, Haynes AE, Stys-Norman D, Evans WK, Lung Cancer Disease Site Group Of Cancer Care Ontario's Program In Evidence-Based Care</AU>
<TI>The role of high-dose-rate brachytherapy in the palliation of symptoms in patients with non-small-cell lung cancer: a systematic review</TI>
<SO>Brachytherapy</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>3</NO>
<PG>189-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vinod-2010" MODIFIED="2012-10-03 15:41:28 +0200" MODIFIED_BY="[Empty name]" NAME="Vinod 2010" TYPE="JOURNAL_ARTICLE">
<AU>Vinod SK, Simonella L, Goldsbury D, Delaney GP, Armstrong B, O'Connell DL</AU>
<TI>Underutilization of radiotherapy for lung cancer in New South Wales, Australia</TI>
<SO>Cancer</SO>
<YR>2010</YR>
<VL>116</VL>
<NO>3</NO>
<PG>686-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2011" MODIFIED="2012-08-30 19:19:22 +0200" MODIFIED_BY="[Empty name]" NAME="Wang 2011" TYPE="JOURNAL_ARTICLE">
<AU>Wang ZM, Lu J, Liu T, Chen KM, Huang G, Liu FJ</AU>
<TI>CT-guided interstitial brachytherapy of inoperable non-small cell lung cancer</TI>
<SO>Lung Cancer</SO>
<YR>2011</YR>
<VL>74</VL>
<NO>2</NO>
<PG>253-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-10-09 11:31:09 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Cardona-2008" MODIFIED="2012-10-09 11:31:09 +0200" MODIFIED_BY="[Empty name]" NAME="Cardona 2008" TYPE="COCHRANE_REVIEW">
<AU>Cardona AF, Reveiz L, Ospina EG, Ospina V, Yepes A</AU>
<TI>Palliative endobronchial brachytherapy for non-small cell lung cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<PG>CD004284</PG>
<IDENTIFIERS MODIFIED="2012-10-09 11:31:09 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-10-09 11:31:09 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004284.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-10-29 06:53:28 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-10-29 06:53:28 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2002-03-13 04:23:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baas-1994">
<CHAR_METHODS MODIFIED="2012-06-27 17:06:23 +0200" MODIFIED_BY="[Empty name]">
<P>Multicenter randomized controlled trial (BRAPHO study).</P>
<P>Netherlands Cancer Institute.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2002-03-13 04:23:26 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with histologically proven inoperable locoregional Non Small Cell Lung Cancer, who were going to be treated with External Radiation Therapy.</P>
<P>Other inclusion criteria: patients' weight loss &lt;10% and functional status &gt;70%.</P>
<P>43 patients, 5 women and 38 men, 37 presented stage III disease and the treatment was considered as palliative. Four patients ineligible.</P>
<P>Age and other clinical details not available.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2002-03-13 04:23:27 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>External Beam Radiation Therapy (EBRT) alone (12 patients).</LI>
</UL>
<UL>
<LI>Photodinamic therapy treated using Photofrin (2 mg/kg, 200 J/cm. 630 nm), previous to EBRT (15 patients).</LI>
</UL>
<UL>
<LI>Endobronchial High Dosis Irradiation (15 Gy at 1 cm distance along the tumor) 2 weeks before EBRT (14 x 2.5 + 8 x 2.5 Gy to the tumor area in four weeks), (12 patients).</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2002-03-13 04:23:27 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Survival.</LI>
<LI>Adverse events: esophagitis, hemoptysis, radiation fibrosis, skin photosensitivity, hemoptysis.</LI>
</UL>
<P>Length of follow-up: not available.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-22 08:40:43 +0200" MODIFIED_BY="[Empty name]">
<P>Information from "interim analysis" published as abstract of communication to congress.</P>
<P>Trial Registration number: not available.</P>
<P>Funding: not available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barber-1993">
<CHAR_METHODS MODIFIED="2012-06-27 17:06:32 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial.</P>
<P>Christie and Wythenshawe Hospitals, Manchester, United Kingdom.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-04 11:34:19 +0200" MODIFIED_BY="[Empty name]">
<P>38 patients with inoperable lung cancer and symptoms related to endobronchial deposits.</P>
<P>Age, sex and clinical details not available.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2002-03-13 04:23:28 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Single dose intraluminal radiotherapy (15 GY at 1 cm radius).</LI>
</UL>
<UL>
<LI>External Beam Radiation Therapy (EBRT) (30 Gy in 8 fractions over 10 days).</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Median survival.</LI>
<LI>Symptom evaluation: hemoptysis, breathlessness, cough, dysphagia, tiredness, anorexia and nausea.</LI>
<LI>Re-treatment.</LI>
<LI>Pulmonary function:re-expansion of pulmonary collapse.</LI>
<LI>Quality of life.</LI>
</UL>
<P>Length of follow-up: not available.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-27 17:06:51 +0200" MODIFIED_BY="[Empty name]">
<P>Information from abstract of communication to congress.</P>
<P>Trial Registration number: not available.</P>
<P>Funding: not available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2002-03-13 04:23:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Calaguas-1997">
<CHAR_METHODS MODIFIED="2012-06-27 17:06:57 +0200" MODIFIED_BY="[Empty name]">
<P>Single center open randomized controlled trial.</P>
<P>Lung Center of the Phils, Quezon city, Filipipines.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-20 09:06:50 +0200" MODIFIED_BY="[Empty name]">
<P>Forty-three patients with primary NSCLC.</P>
<P>All of them received External Beam RadioTherapy prior to the endoluminal treatment.</P>
<P>Age, sex and clinical details not available.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-22 19:46:33 +0200" MODIFIED_BY="[Empty name]">
<P> Three different doses of Endobronchial Radiotherapy: 500, 700 and 900 cGy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-22 08:40:08 +0200" MODIFIED_BY="[Empty name]">
<P>Obstruction scores, host performance status scores (not specified), bronchoscopic and radiologic improvement and clinical findings and the complications related with the procedure.</P>
<P>Length of follow-up: not available.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2002-03-13 04:23:30 +0100" MODIFIED_BY="[Empty name]">
<P>Data from communication to congress.</P>
<P>Trial Registration number: not available.</P>
<P>Funding: not available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chella-2000">
<CHAR_METHODS MODIFIED="2012-06-27 17:07:05 +0200" MODIFIED_BY="[Empty name]">
<P>Single center randomized controlled trial.</P>
<P>University of Pisa, Italy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2002-03-13 04:23:32 +0100" MODIFIED_BY="[Empty name]">
<P>29 patients with NSCLC who had already undergone a previous conventional treatment (11 with surgery followed by EBRT and 18 with chemoradiotherapy).</P>
<P>72% squamous cell-carcinoma, 21% adenocarcinoma and 7% large cell carcinoma.</P>
<P>Sex: 23 males and six females; mean age of 61 years (range 47 to 76).</P>
<P>Inclusion criteria: NSCLC involving central airway and not eligible for further surgical, chemotherapeutic or external beam radiation treatment; an expectation of life of at least 2 months; a performance status score (according to WHO) &#8804; 2.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2002-03-13 04:47:07 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Nd-YAG laser debulking only.</LI>
</UL>
<UL>
<LI>High Dose Rate brachytherapy 15 to 18 days after Nd-YAG laser debulking, on an outpatient basis. The dose prescription was 5 Gy at 0.5 cm, with a total exposition time variable from 10 to 15 min. The treatment was repeated 3 times every 7 days, for a total dose of 15 Gy.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Subjective response: improvement in symptoms.</LI>
</UL>
<UL>
<LI>Objective responses: survival, radiological, pulmonary function tests (FEV1, FVC, FEF<SUB>50</SUB>/FIF<SUB>50</SUB>, PaO<SUB>2, </SUB>Speiser's index, period free from disease progression, the number of further endoscopic treatments, costs, complications and adverse effects.</LI>
</UL>
<P>Length of follow-up: median 17.8 months (range 9 to 35 months)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-13 20:14:58 +0200" MODIFIED_BY="[Empty name]">
<P>Trial Registration number: not available</P>
<P>Funding: not available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2002-03-13 04:23:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferstl-1997">
<CHAR_METHODS MODIFIED="2012-06-27 17:07:28 +0200" MODIFIED_BY="[Empty name]">
<P>Single center randomized controlled trial.</P>
<P>Pneumology and Radiotherapy, Klinikum Innenstadt, University of Munich and Zentralkrankeshaus Gauting, L.V.A. Germany.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-20 09:08:47 +0200" MODIFIED_BY="[Empty name]">
<P>19 patients with advanced central NSCLC either inoperable or not suitable to EBRT, with bronchial stenosis due to tumor growth and no contraindications for chemotherapy.</P>
<P>Age, sex and clinical details not available.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-20 09:09:06 +0200" MODIFIED_BY="[Empty name]">
<P>Group 1 (A) received three course of oral etoposide (150 mg/day during 10 days, 12 day interval) and EBB at day five of the course 1 and 3, with 7.2 Gy at 10 mm distance from the source axis. </P>
<P>Group 2 (B) received EBB alone 2 x 7.2 Gy with a three-week interval.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-20 09:10:12 +0200" MODIFIED_BY="[Empty name]">
<P>The one year survival, mean survival time, remission and adverse effects were reported.</P>
<P>Length of follow-up: not available</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2002-03-13 04:23:37 +0100" MODIFIED_BY="[Empty name]">
<P>Data from communication to congress.</P>
<P>Trial Registration number: not available.</P>
<P>Funding: not available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2002-03-13 04:23:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huber-1995">
<CHAR_METHODS MODIFIED="2012-06-27 17:07:34 +0200" MODIFIED_BY="[Empty name]">
<P>Single center open randomized controlled trial.</P>
<P>Medicine, Pneumology and Radiotherapy, Klinikum Innenstadt, University of Munich and Zentralkrankeshaus Gauting, Zuzamklinik L.V.A. Munich Germany.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2002-03-13 04:23:43 +0100" MODIFIED_BY="[Empty name]">
<P>93 patients with central tumors (substantial occlusion evidenced by bronchoscopic examination) with no alternative treatment options such as surgery, external radiotherapy or chemotherapy, and with no concurrent tumor treatment underway).</P>
<P>
<BR/>There was no selection of patients regarding age, sex, histologic findings, tumor stage, or Karnofsky performance status. Upon entering the study, all patients were staged according to the international staging system for lung cancer as recommended by the American Joint Committee on Cancer. Histological classifications were done following the guidelines of the WHO.</P>
<P>Age: mean 65 years. 82% males. Mean KPS: 60. Tumor stage: I 2.3%, II 4.5%, IIIA 18.2%; IIIB 27.2%, IV 47.7%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-20 09:18:43 +0200" MODIFIED_BY="[Empty name]">
<P>Two different fractionation schedules of endobronchial palliative brachytherapy.<BR/>The first group received brachytherapy with a total dose of 15.4 Gy, delivered in four fractions of 3.8 Gy at 10 mm from the source axis at weekly intervals. </P>
<P>The second group received brachytherapy with a total dose of 14.4 Gy in fractions of 2x7.2 Gy at 10 mm from the source axis with an interval of three weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-20 09:32:38 +0200" MODIFIED_BY="[Empty name]">
<P>Survival time was considered the endpoint of the study. </P>
<P>Causes of death and local tumor control assessed three months after the end of treatment and were also reported.</P>
<P>Median observation time 2.5 years; minimum 3 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-13 20:39:30 +0200" MODIFIED_BY="[Empty name]">
<P>Trial Registration number: not available.</P>
<P>Funding: grants of the Wilhelm-Sander-Stiftung Foundation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2002-03-13 04:23:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huber-1997">
<CHAR_METHODS MODIFIED="2012-06-27 17:07:40 +0200" MODIFIED_BY="[Empty name]">
<P>Single center open randomized controlled trial.</P>
<P>University of Munich and ZentralkranKenhaus Gauting. LVA. Germany</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2002-03-13 04:23:44 +0100" MODIFIED_BY="[Empty name]">
<P>98 patients with inoperable advanced non small cell lung cancer proven by histology or cytology, located in the trachea, mainstream or lobar bronchi, with not further concurrent tumor treatment and Karnofsky performance status greater than 50%.</P>
<P>Mean age 63.5 years, range 39 to 82. 82% males. KPS mean 66.6, range 30 to 80. Tumor stage: IIIA 23.8%, IIIB 45.2%, IV 31%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Forty-two patients were assigned to group 1, and were treated with a mean external radiation dose of 50.5 +/- 14.5 Gy; group 2, received a mean external radiation dose of 50 +/- 12.5 Gy followed by an additional dose 7.44 +/- 2.6 Gy (at 10 mm depth) through EBB applied one week before, and three weeks after completion of EBRT .</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-20 09:38:24 +0200" MODIFIED_BY="[Empty name]">
<P>Survival time was considered the principal end point of the study; assessment of local control, time until observed local recurrence and adverse effects were considered as secondary outcomes.</P>
<P>Median observation time 2.5 years; minimum 3 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-22 08:48:30 +0200" MODIFIED_BY="[Empty name]">
<P>The difference of patients between groups was explained due to the loss of seven patients in group 1 in the early phase of the study who were treated in other hospitals and, therefore, could not be followed and evaluated.</P>
<P>Trial Registration number: not available.</P>
<P>Funding: grants of the Wilhelm-Sander Foundation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2002-03-13 04:23:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Langendijk-2001">
<CHAR_METHODS MODIFIED="2012-06-26 21:04:55 +0200" MODIFIED_BY="[Empty name]">
<P>Multicenter open randomized controlled trial.</P>
<P>Six centers Amsterdam, Heerlen and Maastricht, the Netherlands.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2002-03-13 04:23:44 +0100" MODIFIED_BY="[Empty name]">
<P>95 patients.</P>
<P>Mean age: 68 years, 83% males;Stage (UICC 1992): 58% IIIb, 31% IIIa, 10% I. Performance status: 25% WHO 0, 58% WHO 1, 10% WHO 2, 6% WHO 3.</P>
<P>Inclusion criteria:<BR/>Biopsy proven NSCLC, stage I, II, IIIa or IIIb disease according to the UICC 1992 [1], endobronchial tumor in the proximal main bronchus or lobar bronchus, a World Health Organization performance status 0±3 and no prior or planned chemotherapy, prior surgery, prior radiotherapy, other malignancies, pleuritis carcinomatosa, distant metastases or superior vena cava syndrome.</P>
<P>Exclusion criteria:<BR/>Prior treatment with Neodymium-YAG laser was not allowed and, therefore, patients with a complete obstruction were not eligible.<BR/>Patients requiring two or more catheters were also excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2002-03-13 04:23:45 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>External irradiation alone (47 patients).</LI>
</UL>
<UL>
<LI>External irradiation in combination with EBB (48 patients).</LI>
</UL>
<P>For external irradiation, two fractionation schedules were allowed, i.e. a radical fractionation schedule (60 Gy) or a palliative fractionation schedule (30 Gy).<BR/>Patients with a WHO performance status 3, supraclavicular lymph node metastases and/or distant metastases with symptoms related to intrathoracic tumor were considered to have the worst prognosis and were selected for the palliative fractionation schedule.<BR/>Patients with stage I or II disease (UICC 1992) with a tumor diameter 4 cm or stage IIIa and stage IIIb disease (UICC 1992) without supraclavicular lymph node metastases and a WHO performance 2 were considered to have an intermediate prognosis and were selected for the radical fractionation schedule.<BR/>For patients treated according to the palliative schedule, the target volume was irradiated with 3 Gy per fraction (four times a week) up to a total dose of 30 Gy (100%) without correction for lung tissue density. For patients treated according to the radical schedule, the aforementioned target volume was treated with fraction doses of 2.25 Gy (four times a week) to a total dose of 45 Gy, followed by a boost up to 60 Gy, using fraction doses of 2.5 Gy (four times a week) on the gross tumor volume with a 1 cm margin.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-12 11:30:53 +0200" MODIFIED_BY="[Empty name]">
<P>Quality of life and respiratory symptoms were assessed before the start of radiotherapy and subsequently 2 weeks, 6 weeks and 3, 6 and 12 months after the end of radiotherapy.<BR/>Re-expansion and prevention of atelectasis.<BR/>Response of dyspnea.<BR/>Changes in mean scores for dyspnea.<BR/>Response of other respiratory symptoms and QoL.<BR/>Changes in mean scores of symptoms and quality of life.<BR/>Survival, causes of death and complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2002-03-13 04:23:45 +0100" MODIFIED_BY="[Empty name]">
<P>Trial registration number: not available.</P>
<P>Funding: Dutch Cancer Society. The authors provided additional information by email.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-29 06:53:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mallick-2006">
<CHAR_METHODS MODIFIED="2012-06-26 21:05:33 +0200" MODIFIED_BY="[Empty name]">
<P>Single center open randomized controlled trial (phase II).</P>
<P>Department of Radiotherapy and Pulmonary Medicine. Post-graduate Institute of Medical Education and Research, Chandigarh, India.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2002-03-13 04:23:46 +0100" MODIFIED_BY="[Empty name]">
<P>Forty-five patients with previously untreated, inoperable, locally advanced NSCLC.</P>
<P>Mean age: 64.5 years. 96% males. 89% squamous cell carcinoma, 9% adenocarcinoma and 2% large cell. 60% stage IIIB, 40% stage IIIA. 56% located in lobar bronchus and 44% in main bronchus.</P>
<P>Exclusion criteria: endoscopically-proven endobronchial disease and one or more symptoms of endobronchial disease (dyspnea, cough, hemoptysis or obstructive pneumonia) and a KPS score of 60 to 80.</P>
<P>Exclusion criteria: previously treated patients and those with metastatic disease who would require primary chemotherapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2002-03-13 04:23:46 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Arm A, all patients received external radiation to the dose of 30 Gy in 10 fractions over 2 weeks. Endobronchial application and brachytherapy was carried out at the end of the first and second weeks on days 6 and 13. XRT was not given simultaneously with EBBT on the same day. The dose of EBBT was 8 Gy at 1 cm from the source axis on each of these applications.</LI>
</UL>
<UL>
<LI>Arm B, the same schedule for external radiation was used. Endobronchial application and brachytherapy was carried out at the end of the second week on day 13 with a single fraction of 10 Gy at 1 cm.</LI>
</UL>
<UL>
<LI>Arm C, patients did not receive external radiation. They were treated with a single fraction of EBBT to a dose of 15 Gy at 1 cm.</LI>
</UL>
<P>Endobronchial brachytherapy was performed as an outpatient procedure.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-29 06:53:28 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Endobronchial response: obstruction score.</LI>
</UL>
<UL>
<LI>Symptoms: Speiser symptom score. Symptom response was defined as a reduction of the severity of the symptom characterized by a fall in the symptom score.</LI>
</UL>
<UL>
<LI>Time to relapse was defined as the time for which the symptom severity remained lesser than at presentation.</LI>
</UL>
<UL>
<LI>Time to progression was defined as the time for which the symptoms did not show progression to a higher grade of severity than at presentation.</LI>
</UL>
<UL>
<LI>Quality of life assessment using the EORTC QLQ-C30 and LC-13 version 3 questionnaires was done before treatment and at the end of 1 month following treatment.</LI>
</UL>
<UL>
<LI>Acute and late pulmonary and esophageal toxicity, using RTOG morbidity scoring criteria.</LI>
</UL>
<P>The duration of follow-up: median 6 months, range 2 to 17 months.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2002-03-13 04:23:49 +0100" MODIFIED_BY="[Empty name]">
<P>Trial Registration number: not available.</P>
<P>Funding: none declared. The authors provided additional information by email.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2002-03-13 04:23:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moghissi-1999">
<CHAR_METHODS MODIFIED="2012-06-27 17:07:48 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial. Probably open.</P>
<P>Three centers (Leeds, Cambridge and Manchester), United Kingdom.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-21 12:05:45 +0200" MODIFIED_BY="[Empty name]">
<P>75 patients, with no previous thoracic EBRT, and partial obstruction of the trachea or partial or complete obstruction of a main bronchus, the right intermediate bronchus, or a lobar bronchus by predominantly intraluminal microscopically confirmed NSCLC. Disease had to be locally too advanced for surgical resection or radical radiotherapy with curative intent.</P>
<P>Median age 72 years. 63% males. </P>
<P>WHO performance status: 8% 0, 42% 1, 37% 2, 13% 3.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2002-03-13 04:23:51 +0100" MODIFIED_BY="[Empty name]">
<P>EBRT (the most frequently used regimen was 17 Gy in two fractions) vs endobronchial treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-20 11:26:36 +0200" MODIFIED_BY="[Empty name]">
<P>The trial measured WHO performance status, thoracic symptoms, survival rates and adverse effects.</P>
<P>Length of follow-up: not available.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-22 08:49:20 +0200" MODIFIED_BY="[Empty name]">
<P>Trial Registration number: not available.</P>
<P>Funding:none declared.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poellinger-2000">
<CHAR_METHODS MODIFIED="2012-07-13 20:40:40 +0200" MODIFIED_BY="[Empty name]">
<P>Single center randomized controlled trial.</P>
<P>Medicine, Pneumology and Radiotherapy, Klinikum Innenstadt, University of Munich and Zentralkrankeshaus Gauting, Zuzamklinik L.V.A. Munich Germany.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-20 11:41:56 +0200" MODIFIED_BY="[Empty name]">
<P>142 patients suffering from advanced tumors with inoperable central lung masses and endoluminal tumor growth. (Group 1: 60 patients and group 2: 82 patients).</P>
<P>Randomization resulted in an equal distribution for both groups with respect to the age, gender, tumor stage, Karnofsky performance status and histology.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Investigated different fractionation schedules for palliative endobronchial radiation of central lung tumors: four times 3.8 Gy (administered at 1 cm depth from source axis) per week were compared to twice 7.4 Gy with a three weeks interval.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival, local control and side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]">
<P>Data from communication to congress.</P>
<P>Trial Registration number: not available.</P>
<P>Funding: not available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-1998">
<CHAR_METHODS MODIFIED="2012-07-13 20:40:36 +0200" MODIFIED_BY="[Empty name]">
<P>Single center open randomized controlled trial.</P>
<P>Department of Radiotherapy and Pulmonary Medicine. Post-graduate Institute of Medical Education and Research, Chandigarh, India</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-20 11:47:49 +0200" MODIFIED_BY="[Empty name]">
<P>60 patients with inoperable NSCLC, all with endobronchial disease.</P>
<P>Details on sex, age or other clinical characteristics not available.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]">
<P>All the individuals received a dose of 30 Gy of EBRT divided in 10 fractions over two weeks.</P>
<UL>
<LI>One group treated only with EBRT.</LI>
</UL>
<UL>
<LI>The other group treated also with endobrobrachytherapy delivered using micro-Selectron HDR machine, and dose of 8 Gy at 1 cm from central axis of the source in two sessions.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2002-03-13 04:23:54 +0100" MODIFIED_BY="[Empty name]">
<P>Symptomatic response rates (cough, dyspnea, hemoptysis, obstructive pneumonia).<BR/>Chest x-ray and bronchoscopic examination. The mean duration of symptoms relief.</P>
<P>This study does not report overall survival and time to disease progression.</P>
<P>Length of follow-up: not available.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2002-03-13 04:23:55 +0100" MODIFIED_BY="[Empty name]">
<P>Trial Registration number: none.</P>
<P>Funding: none declared. The authors provided additional information by email.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2002-03-13 04:23:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stout-2000">
<CHAR_METHODS MODIFIED="2012-06-27 17:08:19 +0200" MODIFIED_BY="[Empty name]">
<P>Single center randomized controlled trial.</P>
<P>Christie Hospital NHS Trust, Manchester, United Kingdom.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-09 12:22:00 +0200" MODIFIED_BY="[Empty name]">
<P>One hundred and eight patients with histologically confirmed inoperable NSCLC. Nine, stratified separately, had relapsed after surgery and are excluded from analysis.</P>
<P>Patients with endobronchial tumors were eligible for the trial if (a) their thoracic symptoms were limited to cough, hemoptysis or breathlessness (persistent chest pain or dysphagia due to mediastinal or chest wall involvement were exclusion criteria since EBT alone would not relieve those symptoms), (b) they were fit to undergo therapeutic bronchoscopy or fractionated XRT (WHO performance status 0&#8211;2, namely ambulatory and capable of all self-care and up and about more than 50% of waking hours, whether or not able to work) and (c) there was no clinical evidence of malignant disease beyond the thorax (stage 3 without supraclavicular node involvement).</P>
<P>Mean age 68 years, range 40-84. 79 were male, and squamous carcinoma occurred in 81 patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2002-03-13 04:23:56 +0100" MODIFIED_BY="[Empty name]">
<P>Forty-nine received a single exposure of 15 Gy EBB and 50 received eight exposures of megavoltage EBRT over 10 ± 12 days, giving 30 Gy.</P>
<P>Treatment was given on an outpatient basis.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-09 12:22:00 +0200" MODIFIED_BY="[Empty name]">
<P>Mortality, adverse events.</P>
<P>Clinician and patient assessments for nine key symptoms (cough, hemoptysis, breathlessness, chest pain, dysphagia, anorexia, tiredness, nausea and hoarseness). Quality of life questionnaires.</P>
<P>Length of follow-up: until the death of the patients.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-22 08:51:36 +0200" MODIFIED_BY="[Empty name]">
<P>Trial Registration number: not available.</P>
<P>Funding: not available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2002-03-13 04:23:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sur-2004">
<CHAR_METHODS MODIFIED="2012-06-27 17:08:25 +0200" MODIFIED_BY="[Empty name]">
<P>Single center randomized controlled trial. McMaster University. Hamilton. Ontario. Canada</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-09 11:12:03 +0200" MODIFIED_BY="[Empty name]">
<P>65 patients with inoperable stage III, biopsy-proven NSCLC, who were not suited for/ refused chemoradiotherapy treatment and who had luminal disease demonstrable on bronchoscopy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>All patients received EBRT (30 Gy in 10 fractions, 36 Gy in 18 fractions, or 40 Gy in 20 fractions) followed by either EBRT (20 Gy in 10 fractions over two weeks) or EBB (12 Gy in two fractions over two weeks) at a depth of 10 mm.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-09 12:29:10 +0200" MODIFIED_BY="[Empty name]">
<P>Overall survival rate at one year; median duration of symptom free survival after treatment (hemoptysis, chest pain and dyspnea).</P>
<P>Length of follow-up: not available.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2002-03-13 04:23:56 +0100" MODIFIED_BY="[Empty name]">
<P>Data from communication to congress.</P>
<P>Trial Registration number: not available.</P>
<P>Funding: not available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2002-03-13 05:28:50 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-05-24 11:59:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anacak-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-24 11:59:26 +0200" MODIFIED_BY="[Empty name]">
<P>Phase-II study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bedwinek-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Burt-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Delclos-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Escobar_x002d_Sacristan-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fass-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2002-03-13 04:23:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fernando-2011a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2002-03-13 04:23:57 +0100" MODIFIED_BY="[Empty name]">
<P>Non-palliative intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2002-03-13 04:23:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fernando-2011b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2002-03-13 04:23:58 +0100" MODIFIED_BY="[Empty name]">
<P>non-palliative intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Freitag-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gauwitz-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gejerman-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goldman-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hernandez-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-22 12:02:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mallick-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-22 12:02:27 +0200" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mehta-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ofiara-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ornadel-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Perol-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Speiser-1993a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Speiser-1993b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sutedja-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tr_x00e9_daniel-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-06-27 17:46:21 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2002-03-13 04:24:07 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2002-03-13 04:24:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brachy-2011">
<CHAR_STUDY_NAME MODIFIED="2012-06-12 10:49:38 +0200" MODIFIED_BY="[Empty name]">
<P>Brachy: A Trial to Evaluate the Improvement in Lung Cancer Patients Receiving Radiation With or Without Brachytherapy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-06-22 08:55:57 +0200" MODIFIED_BY="[Empty name]">
<P>Phase III, multi-centre, randomized, parallel, open label.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2002-03-13 04:24:04 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria:</P>
<UL>
<LI>Cytologic or histologic proof of non-small cell lung cancer (NSCLC).</LI>
<LI>Stages III, IV or recurrent disease.</LI>
<LI>Documented endobronchial luminal disease by either endoscopy or CT-imaging.</LI>
<LI>Candidate for palliative thoracic radiation therapy because of cough, shortness of breath or hemoptysis.</LI>
</UL>
<P>Exclusion criteria:</P>
<UL>
<LI>Age less than 18 years.</LI>
<LI>Uncontrolled or symptomatic brain metastases.</LI>
<LI>Anticipated survival of less than 3 months.</LI>
<LI>Systemic therapy planned to begin within 6 weeks following randomization.</LI>
<LI>Systemic therapy within 4 weeks of planned study randomization.</LI>
<LI>Any prior radiotherapy involving the lungs.</LI>
<LI>Cardiac arrest or myocardial infarction within 6 months prior to study randomization.</LI>
<LI>Inability to receive sedation or undergo invasive procedures due to severe chronic obstructive pulmonary disease, bleeding disorders, or other medical conditions which will preclude the use of High Dose Rate Intraluminal Brachytherapy..</LI>
<LI>Prior history of other cancers within the past 3 years, (excluding basal cell skin cancer and carcinoma in-situ of any site, such as cervix or breast).</LI>
<LI>Pregnancy, lactation, or failure to use dual-method contraception in pre-menopausal women.</LI>
<LI>Unwillingness or inability (e.g. incompetence, severe psychiatric disorders) to complete informed consent and the baseline QoL assessments required for the trial.</LI>
<LI>Having received an investigational agent within one month of study randomization.</LI>
<LI>Inability to attend regular follow-up evaluations due to psychiatric or addictive disorder or geographic inaccessibility.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2002-03-13 04:24:05 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Experimental: External Beam Radiation (EBR) plus High Dose Rate Intraluminal Brachytherapy (HDRIB).</LI>
<LI>Active comparator: External Beam Radiation (EBR).</LI>
</UL>
<P>EBR of 20 Gy in 5 daily fractions over one week.</P>
<P>HDRIB of 14 Gy in 2 fractions over two weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2002-03-13 04:24:07 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome measures:</P>
<P>For each subject, a lung cancer-related symptomatic improvement at 6 weeks post randomization, defined as a 10-point improvement on a 100 point scale from the summary question of lung cancer symptoms.<BR/>Secondary outcome measures:</P>
<P>Improvement in each lung cancer symptom as measured by the Lung Cancer Symptom Scale (LCSS) as defined by a 10-point improvement for cough, shortness of breath, hemoptysis and pain on the LCSS at 6 weeks post randomization.<BR/>Improvement in each lung cancer symptom and overall symptoms at any time after randomization.<BR/>A Quality of Life (QOL) improvement as measured be overall score of the LCSS, at each scheduled assessment point following randomization.<BR/>Symptomatic progression-free survival (SPFS), defined as the time from randomization until death, use of chemotherapy, or the first post-randomization score on LCSS #7 which is 10 points or greater than the baseline score, or scored at 100.<BR/>Overall survival, calculated from the date of randomization to the date of death.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-12 09:56:02 +0200" MODIFIED_BY="[Empty name]">
<P>October 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-12 09:55:13 +0200" MODIFIED_BY="[Empty name]">
<P>Jim Wright, <A HREF="mailto:jim.wright%40jcc.hhsc.ca?subject=NCT01351116,%20OCOG-2011-BRACHY,%20A%20Trial%20to%20Evaluate%20the%20Improvement%20in%20Lung%20Cancer%20Patients%20Receiving%20Radiation%20With%20or%20Without%20Brachytherapy">jim.wright@jcc.hhsc.ca</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-12 09:55:46 +0200" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov identifier: NCT01351116</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-10-09 12:35:25 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-09 12:34:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baas-1994">
<DESCRIPTION>
<P>Insufficient information to make judgement. No description of methods of randomization (communication to congress) .</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-09 12:34:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barber-1993">
<DESCRIPTION>
<P>No description of methods of randomization.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-09 12:35:18 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Calaguas-1997">
<DESCRIPTION>
<P>No description of methods of randomization.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 15:46:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chella-2000">
<DESCRIPTION>
<P>No description of methods of randomization. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 15:47:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferstl-1997">
<DESCRIPTION>
<P>No description of methods of randomization. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 16:18:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huber-1995">
<DESCRIPTION>
<P>No description of methods of randomization. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 16:28:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huber-1997">
<DESCRIPTION>
<P>No description of methods of randomization. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-09 12:35:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Langendijk-2001">
<DESCRIPTION>
<P>Central randomization done by the Integral Cancer Center in Amsterdam.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-24 11:39:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mallick-2006">
<DESCRIPTION>
<P>Random number table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-09 12:35:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moghissi-1999">
<DESCRIPTION>
<P>Central randomization. Quote: &#8220;Patients were randomized by the MRC Cancer Division&#8221;. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 16:56:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poellinger-2000">
<DESCRIPTION>
<P>No description of methods of randomization. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-15 11:45:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-1998">
<DESCRIPTION>
<P>Random number table. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 17:09:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stout-2000">
<DESCRIPTION>
<P>No description of methods of randomization. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 12:23:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sur-2004">
<DESCRIPTION>
<P>No description of methods of randomization. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-10-09 12:35:26 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-22 19:33:54 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baas-1994">
<DESCRIPTION>
<P>Insufficient information to make judgement. No description of methods of allocation concealment (communication to congress).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-22 08:41:29 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barber-1993">
<DESCRIPTION>
<P>No description of methods of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-22 08:42:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Calaguas-1997">
<DESCRIPTION>
<P>No description of methods of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 15:46:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chella-2000">
<DESCRIPTION>
<P>No description of methods of allocation concealment. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 15:47:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferstl-1997">
<DESCRIPTION>
<P>No description of methods of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 16:18:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huber-1995">
<DESCRIPTION>
<P>No description of methods of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 16:28:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huber-1997">
<DESCRIPTION>
<P>No description of methods of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-09 12:35:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Langendijk-2001">
<DESCRIPTION>
<P>Central randomization done by the Integral Cancer Center in Amsterdam.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 22:21:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mallick-2006">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-09 12:35:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moghissi-1999">
<DESCRIPTION>
<P>Central randomization. Quote: &#8220;Patients were randomized by the MRC Cancer Division&#8221;. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 16:56:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poellinger-2000">
<DESCRIPTION>
<P>No description of methods of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 22:23:31 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sharma-1998">
<DESCRIPTION>
<P>Not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 17:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stout-2000">
<DESCRIPTION>
<P>No description of methods of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 12:23:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sur-2004">
<DESCRIPTION>
<P>No description of methods of allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-03-16 15:34:13 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>All other outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2002-03-13 04:23:50 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>All other outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-21 18:50:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baas-1994">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-03-21 18:50:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baas-1994">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-16 14:41:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barber-1993">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-06-22 08:41:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barber-1993">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 09:02:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Calaguas-1997">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-06-20 09:03:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Calaguas-1997">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-27 17:07:18 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chella-2000">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-03-16 14:59:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chella-2000">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-27 16:51:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferstl-1997">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-06-20 09:13:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferstl-1997">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-16 16:26:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huber-1995">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-06-20 09:27:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huber-1995">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 09:41:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huber-1997">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-06-20 09:43:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huber-1997">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-16 16:34:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Langendijk-2001">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-03-16 16:34:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Langendijk-2001">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2002-03-13 04:23:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mallick-2006">
<DESCRIPTION>
<P>No losses to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2002-03-13 04:23:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mallick-2006">
<DESCRIPTION>
<P>No losses to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-27 17:07:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moghissi-1999">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-06-27 17:08:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moghissi-1999">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-16 16:59:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poellinger-2000">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-06-20 11:46:20 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poellinger-2000">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-16 17:04:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-1998">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-03-16 17:04:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-1998">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-16 17:11:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stout-2000">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-03-16 17:11:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stout-2000">
<DESCRIPTION>
<P>No follow-up losses reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-22 08:54:34 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sur-2004">
<DESCRIPTION>
<P>Information not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-06-22 08:54:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sur-2004">
<DESCRIPTION>
<P>Information not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-06-27 17:58:32 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 17:58:32 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baas-1994">
<DESCRIPTION>
<P>No access to study protocol to check whether published results cover all outcome measures that were pre-specified as relevant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 14:41:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barber-1993">
<DESCRIPTION>
<P>Authors present results on all outcome measures that were pre-specified as relevant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 09:03:14 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Calaguas-1997">
<DESCRIPTION>
<P>Authors present results on all outcome measures that were pre-specified as relevant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 15:00:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chella-2000">
<DESCRIPTION>
<P>Authors present results on all outcome measures that were pre-specified as relevant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 09:14:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferstl-1997">
<DESCRIPTION>
<P>Authors present results on all outcome measures that were pre-specified as relevant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 16:26:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huber-1995">
<DESCRIPTION>
<P>Authors present results on all outcome measures that were pre-specified as relevant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 16:34:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huber-1997">
<DESCRIPTION>
<P>Authors present results on all outcome measures that were pre-specified as relevant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-22 08:48:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Langendijk-2001">
<DESCRIPTION>
<P>Authors present results on all outcome measures that were pre-specified as relevant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-22 18:07:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mallick-2006">
<DESCRIPTION>
<P>Authors present results on all outcome measures that were pre-specified as relevant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 11:33:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moghissi-1999">
<DESCRIPTION>
<P>Authors present results on all outcome measures that were pre-specified as relevant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 17:00:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poellinger-2000">
<DESCRIPTION>
<P>Authors present results on all outcome measures that were pre-specified as relevant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 17:54:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sharma-1998">
<DESCRIPTION>
<P>Authors present results on all outcome measures that were pre-specified as relevant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 17:13:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stout-2000">
<DESCRIPTION>
<P>Authors present results on all outcome measures that were pre-specified as relevant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 12:23:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sur-2004">
<DESCRIPTION>
<P>Authors present results on all outcome measures that were pre-specified as relevant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2002-03-13 04:23:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baas-1994">
<DESCRIPTION>
<P>Inssufficient data. Communication to congress (i.e. no data on baseline imbalance, differential diagnostic activity).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2002-03-13 04:53:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barber-1993">
<DESCRIPTION>
<P>Inssufficient data. Communication to congress (i.e. no data on baseline imbalance, differential diagnostic activity).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2002-03-13 04:23:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Calaguas-1997">
<DESCRIPTION>
<P>Insufficient data. Communication to congress (i.e. no data on baseline imbalance, differential diagnostic activity).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 15:00:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chella-2000">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 16:06:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferstl-1997">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 16:26:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huber-1995">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 09:43:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huber-1997">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 16:34:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Langendijk-2001">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-22 18:07:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mallick-2006">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 11:22:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moghissi-1999">
<DESCRIPTION>
<P>Quote: "In view of the small number of patients randomized and the high proportion who did not received their allocated treatment, between treatment comparisons are unlikely to be reliable and are not presented in detail".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 11:46:31 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Poellinger-2000">
<DESCRIPTION>
<P>Quote: "Randomization resulted in an equal distribution for both groups with respect to the age, gender, tumor stage, Karnofsky performance status and histology."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-15 12:05:04 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sharma-1998">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 17:13:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stout-2000">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 12:26:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sur-2004">
<DESCRIPTION>
<P>Insufficient information. Communication to congress.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2002-03-13 04:23:51 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2">
<NAME>All other outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-13 20:38:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baas-1994">
<DESCRIPTION>
<P>Probably unblinded (not reported). Objective responses outcomes: survival, adverse events (esophagitis, hemoptysis, radiation fibrosis).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-21 18:49:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baas-1994">
<DESCRIPTION>
<P>Probably unblinded (not reported). Outcomes response: tolerability.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-09 12:34:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barber-1993">
<DESCRIPTION>
<P>Randomized controlled trial (median survival, re-treatment, pulmonary function). Probably open.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-10-09 12:34:57 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barber-1993">
<DESCRIPTION>
<P>Randomized controlled trial (symptom evaluation, quality of life). Probably open.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-22 08:44:54 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Calaguas-1997">
<DESCRIPTION>
<P>Probably unblinded (not reported). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-06-20 09:01:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Calaguas-1997">
<DESCRIPTION>
<P>Clinical response, host performance status scores (not specified), bronchoscopic and radiologic improvement, and the complications related with the procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-20 09:04:18 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chella-2000">
<DESCRIPTION>
<P>Probably unblinded (not reported). Objective responses outcomes: radiological, pulmonary function tests, period free from disease progression, the number of further endoscopic treatments, costs, complications and adverse effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-06-22 08:46:47 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chella-2000">
<DESCRIPTION>
<P>Probably unblinded (not reported). Outcomes: improvement in symptoms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-20 09:15:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferstl-1997">
<DESCRIPTION>
<P>Probably unblinded (not reported). Objective responses outcomes: survival, remission of local tumor, WHO grade 3/4 toxicity.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-06-20 09:11:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferstl-1997">
<DESCRIPTION>
<P>No subjective outcomes measured.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-22 08:48:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huber-1995">
<DESCRIPTION>
<P>Open ? trial. Outcomes: Survival time, causes of death and local tumor control.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-10-09 11:10:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huber-1995">
<DESCRIPTION>
<P>No subjective outcomes assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-22 08:48:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huber-1997">
<DESCRIPTION>
<P>Open? trial. Outcomes: Survival time, assessment of local control, time until observed local recurrence and adverse effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-10-09 11:11:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huber-1997">
<DESCRIPTION>
<P>No subjective outcomes assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-25 12:13:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Langendijk-2001">
<DESCRIPTION>
<P>No, but unlikely to influence objective outcomes: survival, causes of death and complications.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-06-12 11:52:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Langendijk-2001">
<DESCRIPTION>
<P>No, it could bias the assessment of subjective outcomes like dyspnea and scores of symptoms and quality of life.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-26 21:16:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mallick-2006">
<DESCRIPTION>
<P>No, but unlikely to influence objective outcomes: survival, causes of death and complications.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-07-13 20:40:10 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mallick-2006">
<DESCRIPTION>
<P>No, it could bias the assessment of subjective outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-20 11:32:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moghissi-1999">
<DESCRIPTION>
<P>Probably unblinded (not reported). Outcomes: survival rates and adverse effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2002-03-13 04:23:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moghissi-1999">
<DESCRIPTION>
<P>Probably unblinded (not reported). Outcomes WHO performance status, thoracic symptoms and quality of life (Rotterdam Symptom Checklist).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-20 11:45:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poellinger-2000">
<DESCRIPTION>
<P>Probably unblinded (not reported). Outcome: survival, local control and side effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-06-20 11:45:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poellinger-2000">
<DESCRIPTION>
<P>Probably unblinded (not reported). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-09 12:21:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-1998">
<DESCRIPTION>
<P>No. Outcomes: symptomatic response rates (hemoptysis, obstructive pneumonia) and bronchoscopic examination.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-06-15 12:04:32 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sharma-1998">
<DESCRIPTION>
<P>Outcomes: Symptomatic response rates (cough, dyspnea), Chest x-ray, the mean duration of symptoms relief.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-09 12:22:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stout-2000">
<DESCRIPTION>
<P>Probably unblinded (not reported). Objective outcomes: mortality, hemoptysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-06-21 12:23:02 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stout-2000">
<DESCRIPTION>
<P>Probably unblinded (not reported). Subjective outcomes: clinician and patient assessments for other key symptoms (cough, breathlessness, chest pain, dysphagia, anorexia, tiredness, nausea and hoarseness) and quality of life questionnaires.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-22 08:52:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sur-2004">
<DESCRIPTION>
<P>Probably unblinded (not reported). Outcomes: overall survival rate at one year; median free survival.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-06-22 08:54:57 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sur-2004">
<DESCRIPTION>
<P>Probably unblinded (not reported). Open randomized controlled trial. Outcomes: control of any symptom, median of dyspnea control.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-10-09 12:35:14 +0200" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2">
<NAME>All other outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-22 08:40:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baas-1994">
<DESCRIPTION>
<P>Probably unblinded (not reported). Objective responses outcomes: survival, adverse events (esophagitis, hemoptysis, radiation fibrosis).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-06-04 11:12:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baas-1994">
<DESCRIPTION>
<P>Probably unblinded (not reported). Outcomes response: tolerability.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-09 12:35:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barber-1993">
<DESCRIPTION>
<P>Randomized controlled trial (median survival, re-treatment, pulmonary function). Probably open.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-10-09 12:35:14 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barber-1993">
<DESCRIPTION>
<P>Randomized controlled trial (symptom evaluation, quality of life). Probably open.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-22 08:45:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Calaguas-1997">
<DESCRIPTION>
<P>Probably unblinded (not reported).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-06-20 09:02:02 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Calaguas-1997">
<DESCRIPTION>
<P>Clinical response, host performance status scores (not specified), bronchoscopic and radiologic improvement, and the complications related with the procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-22 08:47:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chella-2000">
<DESCRIPTION>
<P>Probably unblinded (not reported). Objective responses outcomes: radiological, pulmonary function tests, period free from disease progression, the number of further endoscopic treatments, costs, complications and adverse effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-06-22 08:47:25 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chella-2000">
<DESCRIPTION>
<P>Probably unblinded (not reported). Outcomes: improvement in symptoms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 09:15:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferstl-1997">
<DESCRIPTION>
<P>Probably unblinded (not reported). Objective responses outcomes: survival, remission of local tumor, WHO grade 3/4 toxicity.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-06-20 09:12:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferstl-1997">
<DESCRIPTION>
<P>No subjective outcomes measured.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-22 08:48:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huber-1995">
<DESCRIPTION>
<P>Open ? trial. Outcomes: Survival time, causes of death and local tumor control.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-10-09 11:10:49 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huber-1995">
<DESCRIPTION>
<P>No subjective outcomes assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-22 08:48:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huber-1997">
<DESCRIPTION>
<P>Open trial. Outcomes: Survival time, assessment of local control, time until observed local recurrence and adverse effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-10-09 11:11:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huber-1997">
<DESCRIPTION>
<P>No subjective outcomes assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-25 12:14:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Langendijk-2001">
<DESCRIPTION>
<P>No, but unlikely to influence objective outcomes: survival, causes of death and complications.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-06-12 12:03:26 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Langendijk-2001">
<DESCRIPTION>
<P>No, it could bias the assessment of subjective outcomes like dyspnea and scores of symptoms and quality of life.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-26 21:16:49 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mallick-2006">
<DESCRIPTION>
<P>No, but unlikely to influence objective outcomes: survival, causes of death and complications.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-07-13 20:40:12 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mallick-2006">
<DESCRIPTION>
<P>No, it could bias the assessment of subjective outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-22 08:49:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moghissi-1999">
<DESCRIPTION>
<P>Probably unblinded (not reported). Outcomes: survival rates and adverse effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-06-20 11:34:07 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moghissi-1999">
<DESCRIPTION>
<P>Probably unblinded (not reported). Outcomes WHO performance status, thoracic symptoms and quality of life (Rotterdam Symptom Checklist).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 11:45:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poellinger-2000">
<DESCRIPTION>
<P>Probably unblinded (not reported). Outcome: survival, local control and side effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-06-20 11:46:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poellinger-2000">
<DESCRIPTION>
<P>Probably unblinded (not reported). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-09 12:21:59 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-1998">
<DESCRIPTION>
<P>No. Outcomes: symptomatic response rates (hemoptysis, obstructive pneumonia) and bronchoscopic examination.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-06-15 12:04:42 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sharma-1998">
<DESCRIPTION>
<P>Outcomes: Symptomatic response rates (cough, dyspnea), Chest x-ray, the mean duration of symptoms relief.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-09 12:22:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stout-2000">
<DESCRIPTION>
<P>Probably unblinded (not reported). Objective outcomes: mortality, hemoptysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-06-21 12:23:17 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stout-2000">
<DESCRIPTION>
<P>Probably unblinded (not reported). Subjective outcomes: clinician and patient assessments for other key symptoms (cough, breathlessness, chest pain, dysphagia, anorexia, tiredness, nausea and hoarseness) and quality of life questionnaires.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-22 08:53:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sur-2004">
<DESCRIPTION>
<P>Probably unblinded (not reported). Outcomes: overall survival rate at one year; median free survival.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-06-22 08:54:54 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sur-2004">
<DESCRIPTION>
<P>Probably unblinded (not reported). Outcomes: control of any symptom, median of dyspnea control.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2002-03-13 04:41:09 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2002-03-13 04:33:46 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Compliance to treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="41" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:33:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="47" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Compliance to treatment EBRT vs EBRT + EBB</NAME>
<GROUP_LABEL_1>EBRT + 
EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2373592605717307" CI_START="0.8856021794660067" EFFECT_SIZE="1.0468085106382978" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="40" LOG_CI_END="0.09249581299305343" LOG_CI_START="-0.05276132332976777" LOG_EFFECT_SIZE="0.01986724483164284" ORDER="678" O_E="0.0" SE="0.08532476091044641" STUDY_ID="STD-Langendijk-2001" TOTAL_1="47" TOTAL_2="48" VAR="0.007280314824424844" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-10-09 11:43:45 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Radiological re-expansion in patients with an atelectasis before RT</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:43:45 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Radiological re-expansion EBRT + EBB vs EBRT + EBB</NAME>
<GROUP_LABEL_1>EBRT + EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0249394745718274" CI_START="0.8859318618301719" EFFECT_SIZE="1.637037037037037" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" LOG_CI_END="0.4807166893612339" LOG_CI_START="-0.05259967898102477" LOG_EFFECT_SIZE="0.21405850519010458" ORDER="679" O_E="0.0" SE="0.31327267472284276" STUDY_ID="STD-Langendijk-2001" TOTAL_1="30" TOTAL_2="26" VAR="0.09813976872800403" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-10-09 11:50:20 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Response rate of dyspnea</NAME>
<DICH_OUTCOME CHI2="0.4787182252686348" CI_END="1.519723417441284" CI_START="0.8723615573178019" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1514114326040932" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.18176455557052207" LOG_CI_START="-0.059303480888620475" LOG_EFFECT_SIZE="0.06123053734095078" METHOD="MH" MODIFIED="2012-06-28 14:59:18 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.489003522202087" P_Q="1.0" P_Z="0.31942043584975455" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="58" WEIGHT="100.0" Z="0.9956496075135063">
<NAME>Response of dyspnea EBRT + EBB vs EBRT</NAME>
<GROUP_LABEL_1>EBRT + EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0768528846259846" CI_START="0.7408102930506388" EFFECT_SIZE="1.2403846153846154" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.317405734061348" LOG_CI_START="-0.13029299206041073" LOG_EFFECT_SIZE="0.09355637100046862" ORDER="680" O_E="0.0" SE="0.26298044786835684" STUDY_ID="STD-Langendijk-2001" TOTAL_1="39" TOTAL_2="43" VAR="0.06915871596104155" WEIGHT="47.3394495412844"/>
<DICH_DATA CI_END="1.3397655416689154" CI_START="0.8568358775995111" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="13" LOG_CI_END="0.1270288036868384" LOG_CI_START="-0.06710235693195193" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2012-06-28 14:59:18 +0200" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.11403360471222074" STUDY_ID="STD-Mallick-2006" TOTAL_1="28" TOTAL_2="15" VAR="0.013003663003663013" WEIGHT="52.6605504587156"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:50:20 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Response of dyspnea EBB 8 Gy x 2 vs EBB 10 Gy x 1</NAME>
<GROUP_LABEL_1>EBB 8 Gy x 2</GROUP_LABEL_1>
<GROUP_LABEL_2>EBB 10 Gy x 1</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2438544435158854" CI_START="0.8219174553274723" EFFECT_SIZE="1.011111111111111" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.09476956196540971" LOG_CI_START="-0.08517179620187228" LOG_EFFECT_SIZE="0.004798882881768708" MODIFIED="2012-06-28 14:59:16 +0200" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.1056984445115498" STUDY_ID="STD-Mallick-2006" TOTAL_1="15" TOTAL_2="13" VAR="0.011172161172161174" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2002-03-13 04:39:22 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Response of respiratory symptoms</NAME>
<DICH_OUTCOME CHI2="2.4760499576825135" CI_END="1.4350062499889373" CI_START="0.47552439384688044" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8260632404316721" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="29" I2="59.61309274486686" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.15685379258903306" LOG_CI_START="-0.3228271993546322" LOG_EFFECT_SIZE="-0.08298670338279956" METHOD="MH" MODIFIED="2012-06-27 15:19:19 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.11559248606182293" P_Q="1.0" P_Z="0.49766835506247686" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10453190108532216" TOTALS="YES" TOTAL_1="69" TOTAL_2="58" WEIGHT="100.0" Z="0.6781629981498102">
<NAME>Response of cough EBRT + EBB vs EBRT</NAME>
<GROUP_LABEL_1>EBRT + EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2391600850392144" CI_START="0.3104025889508359" EFFECT_SIZE="0.6201923076923077" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.09312741578536474" LOG_CI_START="-0.5080746651123899" LOG_EFFECT_SIZE="-0.20747362466351257" ORDER="681" O_E="0.0" SE="0.3531490783176378" STUDY_ID="STD-Langendijk-2001" TOTAL_1="39" TOTAL_2="43" VAR="0.1247142715165971" WEIGHT="34.63204434802491"/>
<DICH_DATA CI_END="1.2407902894276086" CI_START="0.7451349522119974" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="13" LOG_CI_END="0.0936983859785756" LOG_CI_START="-0.12776506457613626" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2012-06-27 15:18:44 +0200" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.13008872711759825" STUDY_ID="STD-Mallick-2006" TOTAL_1="30" TOTAL_2="15" VAR="0.016923076923076943" WEIGHT="65.36795565197508"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 12:23:14 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="39" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Response rate of hemoptysis (EBRT + EBB) vs EBRT</NAME>
<GROUP_LABEL_1>EBRT + EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2910803380723186" CI_START="0.8885383462704487" EFFECT_SIZE="1.071062271062271" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" LOG_CI_END="0.11095326728263806" LOG_CI_START="-0.05132382479250445" LOG_EFFECT_SIZE="0.029814721245066796" ORDER="682" O_E="0.0" SE="0.0953223671694997" STUDY_ID="STD-Langendijk-2001" TOTAL_1="39" TOTAL_2="43" VAR="0.009086353682796915" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="31" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:44:42 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="39" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Response rate of chest pain (EBRT + EBB) vs EBRT</NAME>
<GROUP_LABEL_1>EBRT + EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5313420787543426" CI_START="0.9071160947449481" EFFECT_SIZE="1.178603006189213" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" LOG_CI_END="0.1850722163813393" LOG_CI_START="-0.04233712740453154" LOG_EFFECT_SIZE="0.07136754448840388" ORDER="683" O_E="0.0" SE="0.13358137423422725" STUDY_ID="STD-Langendijk-2001" TOTAL_1="39" TOTAL_2="43" VAR="0.017843983542304674" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:44:50 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="39" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Response rate of pain in the arm/shoulder (EBRT + EBB) vs EBRT</NAME>
<GROUP_LABEL_1>EBRT + EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3956002639973937" CI_START="0.8139545224893197" EFFECT_SIZE="1.0658119658119658" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="30" LOG_CI_END="0.1447610429289827" LOG_CI_START="-0.08939985946422076" LOG_EFFECT_SIZE="0.027680591732380966" ORDER="684" O_E="0.0" SE="0.13754727318092855" STUDY_ID="STD-Langendijk-2001" TOTAL_1="39" TOTAL_2="43" VAR="0.018919252359508983" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:34:51 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="46" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Positive cough response at 8 weeks- Clinician assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>Favours treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0549854072574645" CI_START="0.5217780818957884" EFFECT_SIZE="0.7419354838709677" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="31" LOG_CI_END="0.023246452438081287" LOG_CI_START="-0.2825141680714409" LOG_EFFECT_SIZE="-0.1296338578166798" ORDER="685" O_E="0.0" SE="0.1796053020267749" STUDY_ID="STD-Stout-2000" TOTAL_1="46" TOTAL_2="46" VAR="0.03225806451612903" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="36" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:35:27 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="46" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Positive hemoptysis response at 8 weeks - Clinician assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0540633282886684" CI_START="0.7314263196764792" EFFECT_SIZE="0.8780487804878049" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="41" LOG_CI_END="0.02286670414038405" LOG_CI_START="-0.13582941604528057" LOG_EFFECT_SIZE="-0.05648135595244823" ORDER="686" O_E="0.0" SE="0.09321888655552364" STUDY_ID="STD-Stout-2000" TOTAL_1="46" TOTAL_2="46" VAR="0.008689760810651585" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:35:40 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="46" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Positive breathlessness response at 8 weeks - Clinician assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9986115631240061" CI_START="0.5632820816136991" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="36" LOG_CI_END="-6.034094686968841E-4" LOG_CI_START="-0.249274063747903" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="687" O_E="0.0" SE="0.14607037326319666" STUDY_ID="STD-Stout-2000" TOTAL_1="46" TOTAL_2="46" VAR="0.021336553945249595" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-004.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:35:54 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="46" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Positive chest pain response at 8 weeks - Clinician assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9933350469331041" CI_START="0.5765232895639211" EFFECT_SIZE="0.7567567567567568" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="37" LOG_CI_END="-0.0029042414424514246" LOG_CI_START="-0.2391831440071001" LOG_EFFECT_SIZE="-0.12104369272477575" ORDER="688" O_E="0.0" SE="0.13879139696590537" STUDY_ID="STD-Stout-2000" TOTAL_1="46" TOTAL_2="46" VAR="0.019263051871747525" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="37" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-004.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:36:06 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="46" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Positive dysphagia response at 8 weeks - Clinician assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1087750228771298" CI_START="0.7716849517224533" EFFECT_SIZE="0.925" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="40" LOG_CI_END="0.044843434124861595" LOG_CI_START="-0.11255996864679638" LOG_EFFECT_SIZE="-0.03385826726096737" ORDER="689" O_E="0.0" SE="0.09245953794748173" STUDY_ID="STD-Stout-2000" TOTAL_1="46" TOTAL_2="46" VAR="0.008548766157461814" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-004.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:36:17 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="46" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Positive anorexia response at 8 weeks - Clinician assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0537833750933392" CI_START="0.6157999532199314" EFFECT_SIZE="0.8055555555555556" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="36" LOG_CI_END="0.02275134268791932" LOG_CI_START="-0.2105603484245817" LOG_EFFECT_SIZE="-0.09390450286833116" ORDER="690" O_E="0.0" SE="0.1370484422709803" STUDY_ID="STD-Stout-2000" TOTAL_1="46" TOTAL_2="46" VAR="0.018782275528902215" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-004.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:36:29 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="46" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Positive tiredness response at 8 weeks - Clinician assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0385869322119459" CI_START="0.5630487620903883" EFFECT_SIZE="0.7647058823529411" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="34" LOG_CI_END="0.016442853880117472" LOG_CI_START="-0.24945399202299187" LOG_EFFECT_SIZE="-0.11650556907143719" ORDER="691" O_E="0.0" SE="0.15618912349410125" STUDY_ID="STD-Stout-2000" TOTAL_1="46" TOTAL_2="46" VAR="0.024395042297855607" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="38" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-004.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:34:30 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="46" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Positive nausea response at 8 weeks - Clinician assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1300048894530217" CI_START="0.7986691105707113" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="40" LOG_CI_END="0.05308032264967884" LOG_CI_START="-0.0976331120719834" LOG_EFFECT_SIZE="-0.022276394711152253" ORDER="692" O_E="0.0" SE="0.08852981759903832" STUDY_ID="STD-Stout-2000" TOTAL_1="46" TOTAL_2="46" VAR="0.007837528604118994" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="32" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-004.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-16 12:43:50 +0200" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="46" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Positive hoarseness response at 8 weeks - Clinician assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.940814123575864" CI_START="0.6170175932380573" EFFECT_SIZE="0.7619047619047619" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="42" LOG_CI_END="-0.0264961715559663" LOG_CI_START="-0.20970245260002277" LOG_EFFECT_SIZE="-0.11809931207799451" ORDER="693" O_E="0.0" SE="0.107616276370996" STUDY_ID="STD-Stout-2000" TOTAL_1="46" TOTAL_2="46" VAR="0.011581262939958592" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-004.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:37:35 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Positive cough response at 8 weeks - Patient assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0376732817067322" CI_START="0.4602409330634851" EFFECT_SIZE="0.6910714285714286" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="28" LOG_CI_END="0.01606063454580264" LOG_CI_START="-0.33701475852038065" LOG_EFFECT_SIZE="-0.16047706198728903" ORDER="694" O_E="0.0" SE="0.20739823363845913" STUDY_ID="STD-Stout-2000" TOTAL_1="40" TOTAL_2="43" VAR="0.043014027316352885" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-004.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:37:24 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Positive hemoptysis response at 8 weeks - Patient assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9658829264138592" CI_START="0.6167075820880931" EFFECT_SIZE="0.7717948717948718" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="39" LOG_CI_END="-0.01507551074155654" LOG_CI_START="-0.20992071212375513" LOG_EFFECT_SIZE="-0.11249811143265583" ORDER="695" O_E="0.0" SE="0.11445303579120555" STUDY_ID="STD-Stout-2000" TOTAL_1="40" TOTAL_2="43" VAR="0.01309949740182298" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-004.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:37:46 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Positive breathlessness response at 8 weeks - patient assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2705963200800487" CI_START="0.46403769829869257" EFFECT_SIZE="0.7678571428571429" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.10400759319092963" LOG_CI_START="-0.3334467360441574" LOG_EFFECT_SIZE="-0.11471957142661386" ORDER="696" O_E="0.0" SE="0.2569628384265435" STUDY_ID="STD-Stout-2000" TOTAL_1="40" TOTAL_2="43" VAR="0.0660299003322259" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-004.17" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:37:58 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Positive chest pain response at 8 weeks - Patient assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8230509659846155" CI_START="0.37261485298847324" EFFECT_SIZE="0.5537878787878788" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="33" LOG_CI_END="-0.0845732710324969" LOG_CI_START="-0.4287398374634819" LOG_EFFECT_SIZE="-0.2566565542479894" ORDER="697" O_E="0.0" SE="0.20216514477354058" STUDY_ID="STD-Stout-2000" TOTAL_1="40" TOTAL_2="43" VAR="0.04087074576130663" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-004.18" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:38:08 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Positive dysphagia response at 8 weeks - Patient assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0299395705738856" CI_START="0.6425660840473797" EFFECT_SIZE="0.8135135135135135" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="37" LOG_CI_END="0.01281174418458949" LOG_CI_START="-0.19208220113089275" LOG_EFFECT_SIZE="-0.08963522847315163" ORDER="698" O_E="0.0" SE="0.12035571771970108" STUDY_ID="STD-Stout-2000" TOTAL_1="40" TOTAL_2="43" VAR="0.014485498787824368" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-004.19" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:38:22 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Positive anorexia response at 8 weeks - Patient assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8230509659846155" CI_START="0.37261485298847324" EFFECT_SIZE="0.5537878787878788" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="33" LOG_CI_END="-0.0845732710324969" LOG_CI_START="-0.4287398374634819" LOG_EFFECT_SIZE="-0.2566565542479894" ORDER="699" O_E="0.0" SE="0.20216514477354058" STUDY_ID="STD-Stout-2000" TOTAL_1="40" TOTAL_2="43" VAR="0.04087074576130663" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-004.20" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:38:35 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Positive tiredness response at 8 weeks - Patient assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7760837149534573" CI_START="0.2734983983963042" EFFECT_SIZE="0.4607142857142857" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="28" LOG_CI_END="-0.11009142953899567" LOG_CI_START="-0.563045212546945" LOG_EFFECT_SIZE="-0.3365683210429703" ORDER="700" O_E="0.0" SE="0.2660672942962563" STUDY_ID="STD-Stout-2000" TOTAL_1="40" TOTAL_2="43" VAR="0.07079180509413067" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-004.21" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:38:47 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Positive nausea response at 8 weeks - Patient assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9558028850919553" CI_START="0.5221174096818099" EFFECT_SIZE="0.7064285714285714" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="35" LOG_CI_END="-0.019631662894922585" LOG_CI_START="-0.28223182526719465" LOG_EFFECT_SIZE="-0.15093174408105864" ORDER="701" O_E="0.0" SE="0.15425263526924074" STUDY_ID="STD-Stout-2000" TOTAL_1="40" TOTAL_2="43" VAR="0.02379387548750541" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-004.22" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:38:58 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Positive hoarseness response at 8 weeks - Clinician assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1419479121620693" CI_START="0.6863234884825924" EFFECT_SIZE="0.8852941176470588" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="34" LOG_CI_END="0.057646294823579025" LOG_CI_START="-0.1634711377204026" LOG_EFFECT_SIZE="-0.05291242144841179" ORDER="702" O_E="0.0" SE="0.12988547442527854" STUDY_ID="STD-Stout-2000" TOTAL_1="40" TOTAL_2="43" VAR="0.016870236466679685" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-004.23" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:39:08 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="46" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Good global palliation at 8 weeks - Clinician assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0026124389268185" CI_START="0.6926349778661908" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="42" LOG_CI_END="0.001133088391703794" LOG_CI_START="-0.15949558048695342" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="703" O_E="0.0" SE="0.09435407522405781" STUDY_ID="STD-Stout-2000" TOTAL_1="46" TOTAL_2="46" VAR="0.008902691511387159" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-004.24" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:39:22 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Good global palliation at 8 weeks - Patient assessment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9532806610193129" CI_START="0.538782681861943" EFFECT_SIZE="0.7166666666666667" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="36" LOG_CI_END="-0.020779217318545214" LOG_CI_START="-0.26858637228956894" LOG_EFFECT_SIZE="-0.1446827948040571" ORDER="704" O_E="0.0" SE="0.14556314949517984" STUDY_ID="STD-Stout-2000" TOTAL_1="40" TOTAL_2="43" VAR="0.021188630490956074" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-004.25" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:48:04 +0200" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Response of cough EBRT + EBB vs EBRT during follow-up</NAME>
<GROUP_LABEL_1>EBRT + EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2407902894276086" CI_START="0.7451349522119974" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="13" LOG_CI_END="0.0936983859785756" LOG_CI_START="-0.12776506457613626" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2012-06-27 15:50:34 +0200" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.13008872711759825" STUDY_ID="STD-Mallick-2006" TOTAL_1="30" TOTAL_2="15" VAR="0.016923076923076943" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-004.26" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 12:25:58 +0200" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="22" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Response rate of hemoptysis (EBRT + EBB) vs EBRT during follow-up</NAME>
<GROUP_LABEL_1>EBRT + EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5900245509387498" CI_START="0.922600404156156" EFFECT_SIZE="1.2111801242236024" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="10" LOG_CI_END="0.20140383014114815" LOG_CI_START="-0.0349863594798116" LOG_EFFECT_SIZE="0.08320873533066829" MODIFIED="2012-06-27 15:53:13 +0200" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.13885676753366233" STUDY_ID="STD-Mallick-2006" TOTAL_1="22" TOTAL_2="12" VAR="0.019281201889897542" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-004.27" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:48:21 +0200" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Response rate obstructive pneumonia EBRT + EBB vs EBRT</NAME>
<GROUP_LABEL_1>EBRT + EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5178260660320961" CI_START="0.7300133169368033" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.1812220068094951" LOG_CI_START="-0.13666921738719065" LOG_EFFECT_SIZE="0.022276394711152208" MODIFIED="2012-06-27 15:55:37 +0200" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.1867308786800715" STUDY_ID="STD-Mallick-2006" TOTAL_1="19" TOTAL_2="10" VAR="0.034868421052631576" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-004.28" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:48:32 +0200" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Response of Cough EBB 8 Gy x 2 vs EBB 10 Gy x 1</NAME>
<GROUP_LABEL_1>EBB 8 Gy x 2</GROUP_LABEL_1>
<GROUP_LABEL_2>EBB 10 Gy x 1</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2732251164306965" CI_START="0.6692225867377" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.10490519719658377" LOG_CI_START="-0.1744294097150076" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2012-06-28 14:42:33 +0200" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.16408253082847335" STUDY_ID="STD-Mallick-2006" TOTAL_1="15" TOTAL_2="15" VAR="0.02692307692307691" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-004.29" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 12:26:17 +0200" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Response of hemoptysis EBB 8 Gy x 2 vs EBB 10 Gy x 1</NAME>
<GROUP_LABEL_1>EBB 8 Gy x 2</GROUP_LABEL_1>
<GROUP_LABEL_2>EBB 10 Gy x 1</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.190413673446994" CI_START="0.8400441143324345" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.07569790666658285" LOG_CI_START="-0.07569790666658288" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-06-28 14:59:12 +0200" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.08893065017326408" STUDY_ID="STD-Mallick-2006" TOTAL_1="9" TOTAL_2="13" VAR="0.007908660540239476" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-004.30" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:48:54 +0200" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Response of obstructive pneumonia EBB 8 Gy x 2 vs EBB 10 Gy x 1</NAME>
<GROUP_LABEL_1>EBB 8 Gy x 2</GROUP_LABEL_1>
<GROUP_LABEL_2>EBB 10 Gy x 1</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1376455532352985" CI_START="0.9081850706444424" EFFECT_SIZE="1.3933333333333333" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.3299356957112114" LOG_CI_START="-0.04182564160046588" LOG_EFFECT_SIZE="0.14405502705537276" MODIFIED="2012-06-28 14:46:02 +0200" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.21837444978517806" STUDY_ID="STD-Mallick-2006" TOTAL_1="9" TOTAL_2="10" VAR="0.04768740031897925" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2012-10-16 12:46:22 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Cause of death</NAME>
<DICH_OUTCOME CHI2="4.640263119307068" CI_END="11.08170445462164" CI_START="0.22375495838871168" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5746702255138583" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="7" I2="56.898995841885345" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="1.0446065634886987" LOG_CI_START="-0.6502273319807795" LOG_EFFECT_SIZE="0.19718961575395955" METHOD="MH" MODIFIED="2012-06-27 16:01:46 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0982608318993341" P_Q="1.0" P_Z="0.6483370151701879" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.7276688810603449" TOTALS="YES" TOTAL_1="133" TOTAL_2="103" WEIGHT="100.0" Z="0.4560736554020764">
<NAME>Fatal massive haemoptysis (EBRT +EBB) vs EBRT</NAME>
<GROUP_LABEL_1>EBRT +EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.418394395740633" CI_START="0.5530739818540965" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.533822167809107" LOG_CI_START="-0.25721677147654404" LOG_EFFECT_SIZE="0.13830269816628146" ORDER="705" O_E="0.0" SE="0.4646601886422926" STUDY_ID="STD-Huber-1997" TOTAL_1="56" TOTAL_2="42" VAR="0.2159090909090909" WEIGHT="50.99499080235587"/>
<DICH_DATA CI_END="249.96303318399316" CI_START="0.8630182371455322" EFFECT_SIZE="14.6875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.397875785986883" LOG_CI_START="-0.06398002675526016" LOG_EFFECT_SIZE="1.1669478796158115" ORDER="706" O_E="0.0" SE="1.4461062907875475" STUDY_ID="STD-Langendijk-2001" TOTAL_1="47" TOTAL_2="46" VAR="2.091223404255319" WEIGHT="25.953269534558334"/>
<DICH_DATA CI_END="3.987709581650965" CI_START="0.007422505812621207" EFFECT_SIZE="0.17204301075268819" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6007235218364254" LOG_CI_START="-2.1294494536324464" LOG_EFFECT_SIZE="-0.7643629658980103" MODIFIED="2012-06-27 16:01:46 +0200" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="1.603717120364604" STUDY_ID="STD-Mallick-2006" TOTAL_1="30" TOTAL_2="15" VAR="2.5719086021505375" WEIGHT="23.05173966308579"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="67" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 12:27:31 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="80" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Fatal hemoptysis (EEB 3,8 Gy x 4 vs EEB 7.4Gy x 2 )</NAME>
<GROUP_LABEL_1>EEB 7.4Gy x 2</GROUP_LABEL_1>
<GROUP_LABEL_2>EEB 3,8 Gy x 4</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8153656663795361" CI_START="1.135460226211601" EFFECT_SIZE="1.4357142857142857" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="35" LOG_CI_END="0.25896411746891335" LOG_CI_START="0.05517192601558839" LOG_EFFECT_SIZE="0.15706802174225085" ORDER="707" O_E="0.0" SE="0.11970854204730028" STUDY_ID="STD-Poellinger-2000" TOTAL_1="80" TOTAL_2="60" VAR="0.01433013503909026" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:49:24 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Death due to haemoptysis or tracheomediastinal fistulation ((Etoposide + EBB) vs EBB)</NAME>
<GROUP_LABEL_1>(Etoposide + EBB)</GROUP_LABEL_1>
<GROUP_LABEL_2>EBB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.164618053273272" CI_START="0.04862390678080086" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6195751774205822" LOG_CI_START="-1.313150149869895" LOG_EFFECT_SIZE="-0.3467874862246563" ORDER="708" O_E="0.0" SE="1.1352924243950933" STUDY_ID="STD-Ferstl-1997" TOTAL_1="10" TOTAL_2="9" VAR="1.2888888888888888" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-16 12:46:22 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="46" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Fatal massive haemoptysis (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.628045866809256" CI_START="0.3158783385654361" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7503576281409938" LOG_CI_START="-0.500480154924394" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="709" O_E="0.0" SE="0.7347483055194942" STUDY_ID="STD-Stout-2000" TOTAL_1="46" TOTAL_2="46" VAR="0.5398550724637681" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 12:27:51 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="44" TOTAL_2="49" WEIGHT="0.0" Z="0.0">
<NAME>Fatal hemoptysis (EBB 4 x 3.8 vs EBB 2 x 7.2)</NAME>
<GROUP_LABEL_1>EBB 4 x 3.8</GROUP_LABEL_1>
<GROUP_LABEL_2>EBB 2 x 7.2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.5590822899523555" CI_START="0.5331696837688183" EFFECT_SIZE="1.559090909090909" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6588774311468388" LOG_CI_START="-0.27313455270571024" LOG_EFFECT_SIZE="0.19287143922056427" ORDER="710" O_E="0.0" SE="0.5474684528487135" STUDY_ID="STD-Huber-1995" TOTAL_1="44" TOTAL_2="49" VAR="0.299721706864564" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2012-10-09 11:50:54 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Broncho-pleural fistula</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:50:54 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="48" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Broncho-pleural fistula (EBRT + EBB) vs EBRT</NAME>
<GROUP_LABEL_1>EBRT + EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="70.36913537646561" CI_START="0.12272996468084556" EFFECT_SIZE="2.938775510204082" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8473822148964194" LOG_CI_START="-0.9110493907629471" LOG_EFFECT_SIZE="0.46816641206673604" ORDER="711" O_E="0.0" SE="1.620316379620976" STUDY_ID="STD-Langendijk-2001" TOTAL_1="48" TOTAL_2="47" VAR="2.625425170068027" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2012-10-09 11:51:05 +0200" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Broncho-esofageal fistula</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:51:05 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="48" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Broncho-esofageal fistula (EBRT + EBB) vs EBRT</NAME>
<GROUP_LABEL_1>EBRT + EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="70.36913537646561" CI_START="0.12272996468084556" EFFECT_SIZE="2.938775510204082" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8473822148964194" LOG_CI_START="-0.9110493907629471" LOG_EFFECT_SIZE="0.46816641206673604" ORDER="712" O_E="0.0" SE="1.620316379620976" STUDY_ID="STD-Langendijk-2001" TOTAL_1="48" TOTAL_2="47" VAR="2.625425170068027" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2002-03-13 04:40:28 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Survival rate</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:51:15 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="56" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>6 months survival rate (EBRT + EBB) vs EBRT</NAME>
<GROUP_LABEL_1>EBRT + EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4477478260326375" CI_START="0.6422713417734036" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.1606929214605397" LOG_CI_START="-0.19228145582700354" LOG_EFFECT_SIZE="-0.015794267183231903" ORDER="713" O_E="0.0" SE="0.20733889647004972" STUDY_ID="STD-Huber-1997" TOTAL_1="56" TOTAL_2="42" VAR="0.042989417989417994" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:51:24 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="56" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>One year survival rate (EBRT + EBB) vs EBRT</NAME>
<GROUP_LABEL_1>(EBRT + EBB)</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.837659020481159" CI_START="0.6070695025605659" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.4529602084504672" LOG_CI_START="-0.21676158429447828" LOG_EFFECT_SIZE="0.11809931207799448" ORDER="714" O_E="0.0" SE="0.3933978962347216" STUDY_ID="STD-Huber-1997" TOTAL_1="56" TOTAL_2="42" VAR="0.15476190476190477" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7466270995276414" CI_END="1.2417875834213583" CI_START="0.48519586077040705" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7762153022403833" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="29" I2="42.74679464950244" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.09404731304052687" LOG_CI_START="-0.314082912777104" LOG_EFFECT_SIZE="-0.1100177998682886" METHOD="MH" MODIFIED="2002-03-13 04:40:18 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.18630142628743707" P_Q="1.0" P_Z="0.2906590093885433" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="88" WEIGHT="100.0" Z="1.0566770690320488">
<NAME>One year survival (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3371392848366845" CI_START="0.5460903723264372" EFFECT_SIZE="1.1297297297297297" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.3686845955045248" LOG_CI_START="-0.2627354800884444" LOG_EFFECT_SIZE="0.0529745577080402" ORDER="715" O_E="0.0" SE="0.37089927798309297" STUDY_ID="STD-Moghissi-1999" TOTAL_1="37" TOTAL_2="38" VAR="0.13756627440837968" WEIGHT="34.4089051711991"/>
<DICH_DATA CI_END="1.1085875624335888" CI_START="0.31481543362531095" EFFECT_SIZE="0.5907626208378088" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.04477000180762282" LOG_CI_START="-0.5019439847818202" LOG_EFFECT_SIZE="-0.22858699148709877" ORDER="716" O_E="0.0" SE="0.3211425020005188" STUDY_ID="STD-Stout-2000" TOTAL_1="49" TOTAL_2="50" VAR="0.10313250659115321" WEIGHT="65.5910948288009"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:40:28 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="49" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Two years survival (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6842817181908019" CI_START="0.02472823420008221" EFFECT_SIZE="0.20408163265306123" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.22641473468319032" LOG_CI_START="-1.6068068947402179" LOG_EFFECT_SIZE="-0.6901960800285136" ORDER="717" O_E="0.0" SE="1.0768434597167287" STUDY_ID="STD-Stout-2000" TOTAL_1="49" TOTAL_2="50" VAR="1.1595918367346938" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-008.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:51:44 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="44" TOTAL_2="49" WEIGHT="0.0" Z="0.0">
<NAME>6 months survival rate (EBB 4 x 3.8 vs EBB 2 x 7.2)</NAME>
<GROUP_LABEL_1>EBB (4 x 3.8)</GROUP_LABEL_1>
<GROUP_LABEL_2>EBB (2 x 7.2)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6622515219702985" CI_START="0.4925346709004898" EFFECT_SIZE="0.9048295454545454" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.2206967392669835" LOG_CI_START="-0.3075631928805071" LOG_EFFECT_SIZE="-0.0434332268067618" ORDER="718" O_E="0.0" SE="0.31030249907227314" STUDY_ID="STD-Huber-1995" TOTAL_1="44" TOTAL_2="49" VAR="0.09628764093049808" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-008.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:51:53 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="44" TOTAL_2="49" WEIGHT="0.0" Z="0.0">
<NAME>One year months survival rate (EBB 4 x 3.8 vs EBB 2 x 7.2)</NAME>
<GROUP_LABEL_1>EBB 4 x 3.8</GROUP_LABEL_1>
<GROUP_LABEL_2>EBB 2 x 7.2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5035495252507194" CI_START="0.206209694058202" EFFECT_SIZE="0.5568181818181818" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.17711773784981513" LOG_CI_START="-0.6856909220931252" LOG_EFFECT_SIZE="-0.254286592121655" ORDER="719" O_E="0.0" SE="0.5068180778222312" STUDY_ID="STD-Huber-1995" TOTAL_1="44" TOTAL_2="49" VAR="0.2568645640074212" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2012-10-09 11:52:51 +0200" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Remission in local tumor</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:52:28 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Complete remission in local tumor at 3 months (Etoposide + EBB) vs EBB</NAME>
<GROUP_LABEL_1>Etoposide + EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.379954515299232" CI_START="0.06542835024143234" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.092719049062868" LOG_CI_START="-1.1842340301842182" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="720" O_E="0.0" SE="1.3374935098492586" STUDY_ID="STD-Ferstl-1997" TOTAL_1="10" TOTAL_2="9" VAR="1.7888888888888888" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:52:36 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Partial remission in local tumor at 3 months (Etoposide + EBB) vs EBB</NAME>
<GROUP_LABEL_1>Etoposide + EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1095323316433627" CI_START="0.3839713607844994" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.32418618596189125" LOG_CI_START="-0.41570116708324156" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="721" O_E="0.0" SE="0.43461349368017665" STUDY_ID="STD-Ferstl-1997" TOTAL_1="10" TOTAL_2="9" VAR="0.18888888888888894" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:52:43 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="36" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Complete remission at 3 months (EBB 4 x 3.8 vs EBB 2 x 7.2)</NAME>
<GROUP_LABEL_1>EBB 4 x 3.8</GROUP_LABEL_1>
<GROUP_LABEL_2>EBB 2 x 7.2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="73.23803152516251" CI_START="0.12961927608518836" EFFECT_SIZE="3.081081081081081" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.864736662920095" LOG_CI_START="-0.8873304083811396" LOG_EFFECT_SIZE="0.4887031272694776" ORDER="722" O_E="0.0" SE="1.6165778206340564" STUDY_ID="STD-Huber-1995" TOTAL_1="36" TOTAL_2="37" VAR="2.6133238501659553" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-09 11:52:51 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="36" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Partial remission at 3 months (EBB 4 x 3.8 vs EBB 2 x 7.2)</NAME>
<GROUP_LABEL_1>EBB 4 x 3.8</GROUP_LABEL_1>
<GROUP_LABEL_2>EBB 2 x 7.2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.424725843693348" CI_START="0.5148783756312642" EFFECT_SIZE="0.8564814814814815" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" LOG_CI_END="0.15373130222097336" LOG_CI_START="-0.2882953477168075" LOG_EFFECT_SIZE="-0.06728202274791709" ORDER="723" O_E="0.0" SE="0.25964864224065837" STUDY_ID="STD-Huber-1995" TOTAL_1="36" TOTAL_2="37" VAR="0.06741741741741741" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2012-10-09 11:53:02 +0200" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Bronchoscopy Speiser&#8217;s index</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.01" MODIFIED="2012-10-09 11:53:02 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Speiser&#8217;s index (Nd-YAG laser + EBB) vs Nd-YAG laser</NAME>
<GROUP_LABEL_1>Nd-YAG laser + EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>Nd-YAG laser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.009841851492829" CI_START="-0.009841851492828901" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="6.9" MEAN_2="6.4" ORDER="724" SD_1="0.7" SD_2="0.7" SE="0.26012817353502227" STUDY_ID="STD-Chella-2000" TOTAL_1="14" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2012-10-09 11:53:12 +0200" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Period free from disease</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-011.01" MODIFIED="2012-10-09 11:53:12 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>period free from disease (months) - (Nd-YAG laser + EBB) vs Nd-YAG laser</NAME>
<GROUP_LABEL_1>Nd-YAG laser + EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>Nd-YAG laser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.162214442647285" CI_START="4.437785557352715" EFFECT_SIZE="5.3" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="2.2" ORDER="725" SD_1="1.6" SD_2="0.4" SE="0.4399134113934349" STUDY_ID="STD-Chella-2000" TOTAL_1="14" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2002-03-13 04:41:09 +0100" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Re-treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2002-03-13 04:41:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="38" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>Re-treatment (EBB vs EBRT)</NAME>
<GROUP_LABEL_1>EBB</GROUP_LABEL_1>
<GROUP_LABEL_2>EBRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.452324909850196" CI_START="0.7549114629247038" EFFECT_SIZE="1.8333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.6485868495993918" LOG_CI_START="-0.12210398005022902" LOG_EFFECT_SIZE="0.2632414347745814" ORDER="726" O_E="0.0" SE="0.45270760831732126" STUDY_ID="STD-Barber-1993" TOTAL_1="38" TOTAL_2="38" VAR="0.20494417862838915" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2002-03-13 04:53:37 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2002-03-13 04:53:37 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2002-03-13 04:53:37 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2012-10-09 12:22:26 +0200" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-005.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Cause of death, outcome: 5.1 Fatal massive hemoptysis (EBRT +EBB) vs EBRT.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2012-06-28 14:59:19 +0200" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-003.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Response rate of dyspnea, outcome: 3.1 Response of dyspnea EBRT + EBB vs EBRT.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2002-03-13 04:40:19 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-008.03" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 8 Survival rate, outcome: 8.3 One year survival (EBB vs EBRT ).</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2002-03-13 05:06:11 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2002-03-13 05:06:11 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-08-30 19:34:14 +0200" MODIFIED_BY="[Empty name]">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2002-03-13 05:06:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>MEDLINE (OvidSP)</B>
</P>
<P>1-25: see LCG MEDLINE (OVID) strategy<BR/>26. Lung neoplasms<BR/>27. Non Small Cell Lung Cancer/<BR/>28. 26 or 27<BR/>29 . (Lung or pulmon$ or pneumo$).tw.<BR/>30. (Cancer or neoplas$ or tumor$ or tumour$ or carcinoma$ or adenocarcinoma$).tw.<BR/>31. 29 or 30<BR/>32. NSCLC<BR/>33. exp radiotherapy/<BR/>34. exp radiotherapy, computer-assisted/<BR/>35. exp radiation dosage/<BR/>36. exp radiotherapy dosage/<BR/>37. exp radiotherapy, high-energy/<BR/>38.exp dose fractionation/<BR/>39. exp brachytherapy/<BR/>40. exp radiation oncology/<BR/>41. radiotherapy$.tw.<BR/>42. (thorac$ adj2 radiotherap$).ti,ab.<BR/>43. (radiat$ adj2 therap$).ti,ab.<BR/>44. (thorac$ adj2 radiat$).ti,ab.<BR/>45. irradiation.tw.<BR/>46.((endobronch$ or intralum$ or endolum$) adj2 (brachytherap$ or curietherap$)).ti,ab.</P>
<P>
<B>EMBASE (OvidSP)</B>
</P>
<P>1-19: See LCG EMBASE (OVID)<BR/>20. Lung tumor/<BR/>21. Lung Non small cell cancer/<BR/>22. (Lung or pulmon$ or pneumo$).tw.<BR/>23. (Cancer or neoplas$ or tumor$ or tumour$ or carcinoma$ or adenocarcinoma$).tw.<BR/>24. NSCLC<BR/>25. exp radiotherapy/<BR/>26. exp computer assisted radiotherapy/<BR/>27. exp radiation dose/<BR/>28. exp megavoltage radiotherapy/<BR/>29. exp adjuvant therapy/<BR/>30. exp radiation dose fractionation/<BR/>31. exp brachytherapy/<BR/>32. exp cancer radiotherapy/<BR/>33. Radiotherapy$<BR/>34. (Thorac$ ADJ radiotherap$).ti,ab.<BR/>35. Radiat$ ADJ therap$).ti,ab.<BR/>36. (Thorac ADJ radiat$).ti,ab.<BR/>37. Irradiaition.tw.<BR/>38. ((endobronch$ or intralum$ or endolum$) ADJ (brachytherap$ or curietherap$))</P>
<P>
<B>Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I>)</B>
</P>
<P>1. Lung neoplasms<BR/>2. Non Small Cell Lung Cancer/<BR/>3. 1 or 2<BR/>4 . (Lung or pulmon$ or pneumo$).tw.<BR/>5. (Cancer or neoplas$ or tumor$ or tumour$ or carcinoma$ or<BR/>adenocarcinoma$).tw.<BR/>6. 4 or 5<BR/>7. NSCLC<BR/>8. exp radiotherapy/<BR/>9. exp radiotherapy, computer-assisted/<BR/>10. exp radiation dosage/<BR/>11. exp radiotherapy dosage/<BR/>12. exp radiotherapy, high-energy/<BR/>13. exp dose fractionation/<BR/>14. exp brachytherapy/<BR/>15. exp radiation oncology/<BR/>16. radiotherapy$.tw.<BR/>17. (thorac$ adj2 radiotherap$).ti,ab.<BR/>18. (radiat$ adj2 therap$).ti,ab.<BR/>19. (thorac$ adj2 radiat$).ti,ab.<BR/>20. irradiation.tw.<BR/>21. ((endobronch$ or intralum$ or endolum$) adj2 (brachytherap$ or curietherap$)).ti,ab.</P>
<P>
<B>LILACS</B> </P>
<P>((PT:"randomized controlled trial" OR PT:"controlled clinical trial" OR PT:"multicenter study" OR MH:"randomized controlled trials as topic" OR MH:"controlled clinical trials as topic" OR MH:"multicenter studies as topic" OR MH:"random allocation" OR MH:"double-blind method" OR MH:"single-blind method") OR ((ensaio$ OR ensayo$ OR trial$) AND (azar OR acaso OR placebo OR control$ OR aleat$ OR random$ OR enmascarado$ OR simpleciego OR ((simple$ OR single OR duplo$ OR doble$ OR double$) AND (cego OR ciego OR blind OR mask))) AND clinic$)) AND NOT (MH:animals OR MH:rabbits OR MH:rats OR MH:primates OR MH:dogs OR MH:cats OR MH:swine OR PT:"in vitro")</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>